

SPECIFICATION

1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE

5 TECHNICAL FIELD

[0001] The present invention relates to a pharmaceutically-useful 1,4-disubstituted imidazole derivative including a pharmaceutically acceptable salt thereof, and an anti-tumor agent comprising it as an active
10 ingredient.

BACKGROUND ART

[0002] Conventional cancer treatments are sometimes not expected to bring in meaningful survival effects even if
15 they can induce the regression of tumors, because of the persistent proliferation of malignant tumors, the metastasis or recurrence of cancer, and the resistance to anti-tumor agents. These days, it has been suggested that cancer stem cell (hereinafter referred to as "CSC") is one
20 of the causes of the failure, which is closely involved in the factors such as the persistent proliferation of malignant tumor. CSCs have been identified in almost all types of major cancers in human such as breast cancer, colon cancer, lung cancer, and hematological malignancy
25 (Non-Patent Document 1). Also, CSCs can be greatly

different in the biological feature from normal cancer cells which differentiate from CSCs, and thus the development of an anti-tumor agent whose target is CSCs is expected to lead to a new strategy for cancer treatments
5 (Non-Patent Document 2).

[0003] One of the features in CSCs is the self-renewal ability (Non-Patent Document 3). Reliable methods established for measuring the self-renewal ability of cells include, for example, a method for measuring the sphere-
10 forming ability of cancer cells in non-adherent condition in the absence of serum (Non-Patent Document 4).

[0004] Non-Patent Document 5 discloses that PF-03084014 having an N-imidazolylamide scaffold can inhibit CSCs to exhibit an anti-cancer effect. However, Non-Patent
15 Document 5 does not disclose the compound of formula (1') of the present invention.

PRIOR ART DOCUMENTS

NON-PATENT DOCUMENTS

20 [0005]

Non-Patent Document 1: Boman et al., Journal of Clinical Oncology 26(17): 2795-2799. 2008

Non-Patent Document 2: Lobo et al., Annu Rev Cell Dev Biol 23: 675-99. 2007

25 Non-Patent Document 3: Al-Hajj et al., Oncogene

23(43): 7274-82. 2004

Non-Patent Document 4: Ponti et al., Cancer Res
65(13): 5506-11. 2005

Non-Patent Document 5: Zhang et al., Stem Cells
5 Translational Medicine 2: 233-242. 2013

SUMMARY OF INVENTION

(PROBLEM TO BE SOLVED BY THE INVENTION)

[0006] An object of the present invention is to provide
10 a novel anti-tumor agent whose target is CSCs which are
thought to be closely involved in the persistent
proliferation of malignant tumor, the metastasis or
recurrence of cancer, and the resistance to anti-tumor
agents.

15


(MEANS FOR SOLVING THE PROBLEMS)

[0007] The present inventors have extensively studied to
reach the above object, and then have found that a compound
of the following formula (1') or a pharmaceutically
20 acceptable salt thereof (hereinafter referred to as "the
present compound", as necessary) has a potent inhibitory
effect on the sphere-forming ability of cancer cells and is
highly useful as a novel anti-tumor agent. Based upon the
new findings, the present invention has been completed.

25 [0008] The present invention provides inventions

described below.

[1] A compound of formula (1'):



or a pharmaceutically acceptable salt thereof, wherein ring
 5 Q^1 is optionally-substituted C_{6-10} aryl group, optionally-substituted C_{3-10} cycloalkyl group, or optionally-substituted 5- to 10-membered heteroaryl group;

R^1 and R^2 are independently hydrogen atom, halogen atom, or C_{1-6} alkyl group which may be optionally
 10 substituted with the same or different 1 to 3 halogen atoms;

W^1 is optionally-substituted C_{1-4} alkylene group;

W^2-Q^2 is $-NR^{3a}C(O)-Q^2$, $-NR^{3a}C(O)O-Q^2$, $-NR^{3a}C(O)OCH_2-Q^2$, $-NR^{3a}C(O)NR^{3b}-Q^2$, $-NR^{3a}C(O)NR^{3b}CH_2-Q^2$, $-NR^{3a}C(O)CH_2O-Q^2$, $-NR^{3a}C(O)CH_2-Q^2$, $-NR^{3a}C(O)CH_2CH_2-Q^2$, $-C(O)NR^{3a}-Q^2$, $-C(O)NR^{3a}CH_2-Q^2$, $-C(O)NR^{3a}CH_2CH_2-Q^2$, or $-NR^{3a}C(O)-CR^{3c}=CR^{3d}-Q^2$ wherein R^{3a} and R^{3b} are independently hydrogen atom or C_{1-6} alkyl group;
 15 and R^{3c} and R^{3d} are independently hydrogen atom, fluorine atom, or C_{1-6} alkyl group;

20 ring Q^2 is 5- to 10-membered heteroaryl group;

W^3 is optionally-substituted C_{1-4} alkylene group, optionally-substituted C_{3-4} alkenylene group, or optionally-

substituted C₃₋₄ alkynylene group;

n is 1, 2, 3, 4, or 5;

R⁴ is, independently when two or more exist, hydrogen atom, halogen atom, optionally-substituted C₁₋₆ alkyl group, optionally-substituted C₁₋₆ alkoxy group, optionally-substituted C₃₋₁₀ cycloalkyl group, optionally-substituted C₂₋₆ alkenyl group, optionally-substituted C₂₋₆ alkynyl group, cyano group, optionally-substituted C₁₋₆ alkyl-carbonyl group, optionally-substituted C₁₋₆ alkylsulfonyl group, optionally-substituted C₁₋₆ alkoxy-carbonyl group, optionally-substituted C₁₋₆ alkyl-carbonylamino group, optionally-substituted C₁₋₆ alkylsulfonylamino group, optionally-substituted C₁₋₆ alkoxy-carbonylamino group, optionally-substituted C₁₋₆ alkyl-carbonyloxy group, optionally-substituted amino group, optionally-substituted aminocarbonyl group, optionally-substituted aminosulfonyl group, optionally-substituted 5- or 6-membered cyclic amino group, optionally-substituted 5- or 6-membered cyclic aminocarbonyl group, nitro group, or carboxyl group;

when R⁴ and W³ are attached to the adjacent carbon atoms on ring Q², they may be combined with the carbon atoms to form 5- to 8-membered cycloalkane ring; and

R⁵ is

(1) hydroxy group,

(2) C₁₋₆ alkoxy group which may be optionally substituted


with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, C₁₋₆ alkoxy, and C₆₋₁₀ aryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(3) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups, or

(4) C₁₋₆ alkyl-carbonylamino group wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 halogen atoms.

[0009]

[2] A compound of formula (1):



or a pharmaceutically acceptable salt thereof, wherein ring Q¹ is optionally-substituted C₆₋₁₀ aryl group, optionally-substituted C₃₋₁₀ cycloalkyl group, or optionally-substituted 5- to 10-membered heteroaryl group;

R¹ and R² are independently hydrogen atom, halogen atom, or C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

W^1 is optionally-substituted C_{1-4} alkylene group;

W^2-Q^2 is $-NR^{3a}C(O)-Q^2$, $-NR^{3a}C(O)O-Q^2$, $-NR^{3a}C(O)OCH_2-Q^2$, $-NR^{3a}C(O)NR^{3b}-Q^2$, $-NR^{3a}C(O)NR^{3b}CH_2-Q^2$, $-NR^{3a}C(O)CH_2O-Q^2$, $-NR^{3a}C(O)CH_2-Q^2$, $-NR^{3a}C(O)CH_2CH_2-Q^2$, $-C(O)NR^{3a}-Q^2$, $-C(O)NR^{3a}CH_2-Q^2$, or $-C(O)NR^{3a}CH_2CH_2-Q^2$ wherein R^{3a} and R^{3b} are independently hydrogen atom or C_{1-6} alkyl group;

ring Q^2 is 5- to 10-membered heteroaryl group;

W^3 is optionally-substituted C_{1-4} alkylene group, optionally-substituted C_{3-4} alkenylene group, or optionally-substituted C_{3-4} alkynylene group;

n is 1, 2, 3, 4, or 5;

R^4 is, independently when two or more exist, hydrogen atom, halogen atom, optionally-substituted C_{1-6} alkyl group, optionally-substituted C_{1-6} alkoxy group, optionally-substituted C_{3-10} cycloalkyl group, optionally-substituted C_{2-6} alkenyl group, optionally-substituted C_{2-6} alkynyl group, cyano group, or optionally-substituted amino group;

when R^4 and W^3 are attached to the adjacent carbon atoms on ring Q^2 , they may be combined with the carbon atoms to form 5- to 8-membered cycloalkane ring; and

R^5 is

(1) hydroxy group,

(2) C_{1-6} alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy,

C₁₋₆ alkoxy, and C₆₋₁₀ aryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

5 (3) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups, or

(4) C₁₋₆ alkyl-carbonylamino group wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 halogen atoms.

10 [0010]

[3] The compound according to [1] or [2] or a pharmaceutically acceptable salt thereof wherein ring Q¹ is

(1) C₆₋₁₀ aryl group which may be optionally substituted with the same or different 1 to 5 groups independently

15 selected from the group consisting of

(a) halogen atom,

(b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆
20 alkoxy,

(c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆
alkoxy,

25 (d) cyano,

(e) C₆₋₁₀ aryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

5 (f) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

10 (g) C₆₋₁₀ aryloxy which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(h) hydroxy,

15 (i) amino which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups,

(j) aminocarbonyl wherein the amino moiety thereof may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups,

20 (k) C₁₋₆ alkoxy carbonyl wherein the alkoxy moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

25 (l) C₁₋₆ alkyl-carbonyl wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group

consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(m) C₁₋₆ alkylsulfonyl wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of
5 halogen atom, hydroxy, and C₁₋₆ alkoxy,

(n) C₁₋₆ alkyl-carbonylamino wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

10 (o) C₁₋₆ alkylsulfonylamino wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(p) C₁₋₆ alkoxy-carbonylamino wherein the alkoxy moiety
15 thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(q) C₁₋₆ alkyl-carboxyloxy wherein the alkyl moiety thereof may be optionally substituted with the same or different 1
20 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(r) aminosulfonyl wherein the amino moiety thereof may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups, and

25 (s) C₃₋₁₀ cycloalkyl which may be optionally substituted

with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(2) C₃₋₁₀ cycloalkyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of (a) to (s) defined in the above (1), or

(3) 5- to 10-membered heteroaryl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of (a) to (s) defined in the above (1);

W¹ is C₁₋₄ alkylene group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy;

W³ is

(1) C₁₋₄ alkylene group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(2) C₃₋₄ alkenylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or

(3) C₃₋₄ alkynylene group which may be optionally substituted with the same or different 1 to 2 halogen

atoms; and

R^4 is, independently when two or more exist,

(1) hydrogen atom,

(2) halogen atom,

5 (3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy,

(4) C_{1-6} alkoxy group which may be optionally substituted
10 with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy,

(5) C_{3-10} cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups
15 independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy,

(6) C_{2-6} alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(7) C_{2-6} alkynyl group which may be optionally substituted
20 with the same or different 1 to 2 halogen atoms,

(8) cyano group, or

(9) amino group which may be optionally substituted with the same or different 1 to 2 C_{1-6} alkyl groups;

when R^4 and W^3 are attached to the adjacent carbon
25 atoms on ring Q^2 , they may combined with the carbon atoms

to form 5- to 8-membered cycloalkane ring.

[0011]

[4] The compound according to any one of [1] to [3] or a pharmaceutically acceptable salt thereof wherein ring Q¹ is

5 (1) phenyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of

(a) halogen atom,

10 (b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

15 (c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(d) cyano,

20 (e) phenyl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

25 (f) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy, and

(g) phenoxy which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

5 (2) C₃₋₇ cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of (a) to (g) defined in the above (1), or

(3) pyridyl group which may be optionally substituted with
10 the same or different 1 to 4 groups independently selected from the group consisting of (a) to (g) defined in the above (1).

[0012]

[5] The compound according to any one of [1] to [4] or a
15 pharmaceutically acceptable salt thereof wherein ring Q¹ is phenyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of

(a) halogen atom,

20 (b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 halogen atoms.

[0013]

25 [6] The compound according to any one of [1] to [5] or a

pharmaceutically acceptable salt thereof wherein W^1 is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with the same or different 1 to 4 halogen atoms.

[0014]

[7] The compound according to any one of [1] to [6] or a pharmaceutically acceptable salt thereof wherein W^2-Q^2 is $-NR^{3a}C(O)-Q^2$, $-NR^{3a}C(O)CH_2O-Q^2$, or $-C(O)NR^{3a}-Q^2$ wherein R^{3a} is hydrogen atom or C_{1-6} alkyl group.

[0015]

[8] The compound according to any one of [1] to [7] or a pharmaceutically acceptable salt thereof wherein W^2-Q^2 is $-NHC(O)-Q^2$ or $-C(O)NH-Q^2$.

[0016]

[9] The compound according to any one of [1] to [8] or a pharmaceutically acceptable salt thereof wherein ring Q^2 is pyridyl group, pyrimidyl group, pyridazyl group, pyrazyl group, oxazolyl group, thiazolyl group, isoxazolyl group, isothiazolyl group, quinolinyl group, isoquinolinyl group, quinazolinyl group, or quinoxalinyl group.

[0017]

[10] The compound according to any one of [1] to [9] or a pharmaceutically acceptable salt thereof wherein ring Q^2 is pyridyl group, pyridazyl group, pyrazyl group, oxazolyl


group, thiazolyl group, isoxazolyl group, or quinolinyl group.

[0018]

[11] The compound according to any one of [1] to [10] or a
 5 pharmaceutically acceptable salt thereof wherein W^3 is
 methylene group which may be optionally substituted with
 the same or different 1 to 2 halogen atoms, or ethylene
 group which may be optionally substituted with the same or
 different 1 to 4 groups independently selected from the
 10 group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy;
 and R^5 is hydroxy group, or C_{1-6} alkoxy group which may be
 optionally substituted with the same or different 1 to 3
 groups independently selected from the group consisting of
 halogen atom, hydroxy, and C_{1-6} alkoxy.

[0019]

[12] The compound according to claim 1 which is represented
 by formula (1a'):



or a pharmaceutically acceptable salt thereof, wherein ring
 20 Q^{1a} is phenyl group, pyridyl group, or cyclohexyl group;

m is 1, 2, 3, 4, or 5;

R^{11} is, independently when two or more exist,

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or

5 (4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

R¹ and R² are independently hydrogen atom, halogen atom, or C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms;
10

W^{1a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with the same or different 1 to 4 halogen atoms;

15 W^{2a}-Q^{2a} is -NR^{3a}C(O)-Q^{2a}, -NR^{3a}C(O)CH₂O-Q^{2a}, -C(O)NR^{3a}-Q^{2a}, or -NR^{3a}C(O)-CH=CH-Q^{2a} wherein R^{3a} is hydrogen atom or C₁₋₆ alkyl group;

ring Q^{2a} is 5- or 6-membered heteroaryl group;

W^{3a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy;
20

25 R¹² and R¹³ are independently

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(5) C₃₋₁₀ cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(6) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(7) C₂₋₆ alkynyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(8) cyano group, or

(9) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups;


when R¹³ and W^{3a} are attached to the adjacent carbon atoms on ring Q², they may combined with the carbon atoms to form 5- or 6-membered cycloalkane ring; and

R¹⁴ is hydroxy group, or C₁₋₆ alkoxy group which may be

optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy.

[0020]

5 [13] The compound according to claim 1 which is represented by formula (1a):



or a pharmaceutically acceptable salt thereof, wherein ring Q^{1a} is phenyl group, pyridyl group, or cyclohexyl group;

10 m is 1, 2, 3, 4, or 5;

R¹¹ is, independently when two or more exist,

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted
15 with the same or different 1 to 3 halogen atoms, or

(4) C₁₋₆ alkoxy group which may be optionally substituted
with the same or different 1 to 3 halogen atoms;

R¹ and R² are independently hydrogen atom, halogen
atom, or C₁₋₆ alkyl group which may be optionally
20 substituted with the same or different 1 to 3 halogen
atoms;

W^{1a} is methylene group which may be optionally

substituted with the same or different 1 to 2 halogen atoms,
or ethylene group which may be optionally substituted with
the same or different 1 to 4 halogen atoms;

$W^{2a}-Q^{2a}$ is $-NR^{3a}C(O)-Q^{2a}$, $-NR^{3a}C(O)CH_2O-Q^{2a}$, or $-C(O)NR^{3a}-$
5 Q^{2a} wherein R^{3a} is hydrogen atom or C_{1-6} alkyl group;

ring Q^{2a} is 5- or 6-membered heteroaryl group;

W^{3a} is methylene group which may be optionally
substituted with the same or different 1 to 2 halogen atoms,
or ethylene group which may be optionally substituted with
10 the same or different 1 to 4 groups independently selected
from the group consisting of halogen atom, hydroxy, and C_{1-6}
alkoxy;

R^{12} and R^{13} are independently

- (1) hydrogen atom,
- 15 (2) halogen atom,
- (3) C_{1-6} alkyl group which may be optionally substituted
with the same or different 1 to 3 groups independently
selected from the group consisting of halogen atom, hydroxy,
and C_{1-6} alkoxy,
- 20 (4) C_{1-6} alkoxy group which may be optionally substituted
with the same or different 1 to 3 groups independently
selected from the group consisting of halogen atom, hydroxy,
and C_{1-6} alkoxy,
- (5) C_{3-10} cycloalkyl group which may be optionally
25 substituted with the same or different 1 to 4 groups

independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(6) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

5 (7) C₂₋₆ alkynyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(8) cyano group, or

(9) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups;

10 when R¹³ and W^{3a} are attached to the adjacent carbon atoms on ring Q^{2a}, they may be combined with the carbon atoms to form 5- or 6-membered cycloalkane ring; and

R¹⁴ is hydroxy group, or C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3
15 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy.

[0021]

[14] The compound according to [12] or [13] or a pharmaceutically acceptable salt thereof wherein ring Q^{1a}
20 is phenyl group.

[0022]

[15] The compound according to any one of [12] to [14] or a pharmaceutically acceptable salt thereof wherein W^{2a}-Q^{2a} is -NHC(O)-Q^{2a}.

25 [0023]

[16] The compound according to any one of [12] to [14] or a pharmaceutically acceptable salt thereof wherein $W^{2a}-Q^{2a}$ is $-C(O)NH-Q^{2a}$.

[0024]

5 [17] The compound according to any one of [12] to [16] or a pharmaceutically acceptable salt thereof wherein ring Q^{2a} is pyridyl group, pyrimidyl group, pyridazyl group, pyrazyl group, oxazolyl group, thiazolyl group, isoxazolyl group, or isothiazolyl group.

10 [0025]

[18] The compound according to any one of [12] to [16] or a pharmaceutically acceptable salt thereof wherein ring Q^{2a} is pyridyl group, pyridazyl group, pyrazyl group, oxazolyl group, thiazolyl group, or isoxazolyl group.

15 [0026]

[19] The compound according to any one of [12] to [16] or a pharmaceutically acceptable salt thereof wherein ring Q^{2a} is pyridyl group.

[0027]

20 [20] The compound according to any one of [12] to [19] or a pharmaceutically acceptable salt thereof wherein R^{12} and R^{13} are independently

(1) hydrogen atom,

(2) halogen atom,

25 (3) C_{1-6} alkyl group which may be optionally substituted

with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(4) C₁₋₆ alkoxy group which may be optionally substituted
5 with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(5) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or

10 (6) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups.

[0028]

[21] The compound according to any one of [12] to [20] or a pharmaceutically acceptable salt thereof wherein R¹² and R¹³
15 are independently

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently
20 selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy, or

(4) amino group.

[0029]

[22] The compound according to any one of [12] to [21] or a
25 pharmaceutically acceptable salt thereof wherein R¹³ is

halogen atom, C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or amino group; and R¹² is hydrogen atom.

[0030]


5 [23] The compound according to any one of [12] to [22] or a pharmaceutically acceptable salt thereof wherein W^{3a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms; and R¹⁴ is hydroxy group.

10 [0031]

[24] The compound according to any one of [1] to [23] or a pharmaceutically acceptable salt thereof wherein R¹ and R² are hydrogen atom.

[0032]

15 [25] The compound according to [1] which is represented by formula (1b):



or a pharmaceutically acceptable salt thereof, wherein X¹ is N or CR²⁶;

20 X² is N or CR²⁸;

provide that at least one of X¹ and X² is N;

R²¹, R²², R²³, R²⁴, and R²⁵ are independently

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or

5 (4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

W^{2b} is -NHC(O)- or -C(O)NH-;

R²⁶, R²⁷, R²⁸, and R²⁹ are independently

(1) hydrogen atom,

10 (2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

15 (4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(5) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or

(6) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups.

[0033]

[26] The compound according to [25] or a pharmaceutically acceptable salt thereof wherein R²² is halogen atom or C₁₋₆

alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms.

[0034]

[27] The compound according to [25] or a pharmaceutically acceptable salt thereof wherein R^{22} is halogen atom or trifluoromethyl group.

[0035]

[28] The compound according to any one of [25] to [27] or a pharmaceutically acceptable salt thereof wherein R^{21} , R^{23} , R^{24} , and R^{25} are independently

(1) hydrogen atom,

(2) halogen atom, or

(3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms.

[0036]

[29] The compound according to any one of [25] to [28] or a pharmaceutically acceptable salt thereof wherein W^{2b} is -NHC(O)-.

[0037]

[30] The compound according to any one of [25] to [29] or a pharmaceutically acceptable salt thereof wherein X^1 is N.

[0038]

[31] The compound according to any one of [25] to [30] or a pharmaceutically acceptable salt thereof wherein X^1 is N; and X^2 is CH.

[0039]

[32] The compound according to any one of [25] to [31] or a pharmaceutically acceptable salt thereof wherein R^{27} is halogen atom, C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or amino group; and R^{29} is hydrogen atom.

[0040]


[33] The compound according to any one of [25] to [32] or a pharmaceutically acceptable salt thereof wherein R^{27} is methyl group substituted with 1 to 3 fluorine atoms; and R^{29} is hydrogen atom.

[0041]

[34] The compound according to any one of [25] to [33] or a pharmaceutically acceptable salt thereof wherein R^{27} is methyl group substituted with 2 fluorine atoms; and R^{29} is hydrogen atom.

[0042]

[35] The compound according to [1] which is represented by formula (1c):



or a pharmaceutically acceptable salt thereof, wherein R^{32}

is halogen atom or C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms; and

5 R³³ and R³⁴ are independently hydrogen atom, or halogen atom.

[0043]

[36] The compound according to [35] or a pharmaceutically acceptable salt thereof wherein R³² is fluorine atom, chlorine atom, or trifluoromethyl group.

10 [0044]

[37] The compound according to [1] selected from the following compounds or a pharmaceutically acceptable salt thereof:

15 6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 10),

6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide (Example 12),

20 5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide (Example 17),

5-(difluoromethyl)-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 18),

25 6-(hydroxymethyl)-5-(trifluoromethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide (Example 19),

6-(hydroxymethyl)-5-methyl-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 39),

6-(hydroxymethyl)-5-methyl-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide
 5 (Example 42),

5-amino-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide
 (Example 45),

5-amino-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 46),
 10

N-[1-(3,4-difluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 54),

N-[1-(3-chlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 55),
 15

5-(difluoromethyl)-N-{1-[4-fluoro-3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-6-(hydroxymethyl)nicotinamide (Example 57),

5-(difluoromethyl)-N-{1-[3-fluoro-5-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-6-(hydroxymethyl)nicotinamide (Example 60),
 20

N-[1-(3-chloro-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 61),

N-[1-(3-bromo-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 62),
 25

5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[3-methoxy-

5-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide
(Example 65),

5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[4-methyl-3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide

5 (Example 70),

N-[1-(3,4-dichlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 71),

N-[1-(3,5-dichlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 75),

10 N-[1-(3-bromo-5-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 76),

N-[1-(3-chloro-5-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 78),

15 N-[1-(3,5-difluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 79),

and

6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]pyridazine-3-carboxamide (Example 85).

[0045]

20 [38] The compound according to [1] selected from the following compounds or a pharmaceutically acceptable salt thereof:

5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide

25 (Example 17),

5-(difluoromethyl)-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 18),

N-[1-(3,4-difluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 54),

5 N-[1-(3-chlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 55),

5-(difluoromethyl)-N-{1-[4-fluoro-3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-6-(hydroxymethyl)nicotinamide (Example 57),

10 N-[1-(3-bromobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 58),

5-(difluoromethyl)-N-{1-[3-fluoro-5-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-6-(hydroxymethyl)nicotinamide (Example 60),

15 N-[1-(3-chloro-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 61),

N-[1-(3-bromo-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 62),

20 5-(difluoromethyl)-6-(hydroxymethyl)-N-[1-(3-methylbenzyl)-1H-imidazol-4-yl]nicotinamide (Example 63),

5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[3-methoxy-5-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide (Example 65),

25 N-[1-(4-chloro-3-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 66),

N-[1-(4-bromo-3-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 67),

5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[4-methyl-3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide

5 (Example 70),

N-[1-(3,4-dichlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 71),

5-(difluoromethyl)-N-{1-[3-fluoro-4-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-6-

10 (hydroxymethyl)nicotinamide (Example 74),

N-[1-(3,5-dichlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 75),

N-[1-(3-bromo-5-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 76),

15 N-[1-(3-chloro-5-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 78),

N-[1-(3,5-difluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 79),

and

20 N-[1-(3-bromo-4-chlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 80).

[0046]

[39] The compound according to [1] selected from the following compounds or a pharmaceutically acceptable salt

25 thereof:

6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide (Example 12),

5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide
5 (Example 17),

5-(difluoromethyl)-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 18),

6-(hydroxymethyl)-5-methyl-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 39),

10 5-amino-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide
(Example 45),

5-amino-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 46),

15 5-(difluoromethyl)-N-{1-[4-fluoro-3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-6-(hydroxymethyl)nicotinamide (Example 57),

5-(difluoromethyl)-N-{1-[3-fluoro-5-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-6-(hydroxymethyl)nicotinamide (Example 60),
20

N-[1-(3-chloro-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 61),

N-[1-(3-bromo-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 62),

25 5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[4-methyl-3-

(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide

(Example 70),

N-[1-(3,4-dichlorobenzyl)-1H-imidazol-4-yl]-5-

(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 71),

5 N-[1-(3,5-dichlorobenzyl)-1H-imidazol-4-yl]-5-

(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 75),

N-[1-(3-bromo-5-fluorobenzyl)-1H-imidazol-4-yl]-5-

(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 76),

N-[1-(3-chloro-5-fluorobenzyl)-1H-imidazol-4-yl]-5-

10 (difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 78),

and

N-[1-(3,5-difluorobenzyl)-1H-imidazol-4-yl]-5-

(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 79).

[0047]

15 [40] A medicament comprising the compound according to any one of [1] to [39] or a pharmaceutically acceptable salt thereof as an active ingredient.

[0048]

[41] An anti-tumor agent comprising the compound according to any one of [1] to [39] or a pharmaceutically acceptable salt thereof as an active ingredient.

[0049]

[42] The anti-tumor agent according to [41] wherein the tumor is acute leukemia, chronic lymphatic leukemia, chronic myelocytic leukemia, polycythemia vera, malignant

25

lymphoma, myeloma, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small-cell lung cancer, non-small cell lung cancer, breast cancer, stomach cancer, gallbladder or bile duct cancer, liver cancer, pancreatic
5 cancer, colon cancer, rectal cancer, ovarian cancer, chorioepithelioma, endometrial cancer, cervical cancer, urothelial cancer, renal cell cancer, prostate cancer, testicular tumor, Wilms' tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, or soft
10 tissue sarcoma.

[0050]

[43] A medicament comprising the compound according to any one of [1] to [39] or a pharmaceutically acceptable salt thereof in combination with another anti-cancer agent
15 selected from the group consisting of an anticancer alkylating agent, an anticancer antimetabolite, an anticancer antibiotic, a plant-based anti-cancer agent, an anticancer platinum coordination compound, an anticancer camptothecin derivative, an anticancer tyrosine kinase
20 inhibitor, a serine-threonine kinase inhibitor, a phospholipid kinase inhibitor, a monoclonal antibody, an interferon, a biological response modifier, a hormone preparation, an immune checkpoint inhibitor, an epigenetics-related molecule inhibitor, a post-
25 translational protein modification inhibitor, and other anti-cancer agent or a pharmaceutically acceptable

salt thereof.

[0051]

[44] A method for treating cancer which comprises administering a therapeutically effective amount of the compound according to any one of [1] to [39] or a pharmaceutically acceptable salt thereof to a patient in need thereof.

[0052]

[45] Use of the compound according to any one of [1] to [39] or a pharmaceutically acceptable salt thereof for the manufacture of an agent for treating cancer.

[0053]

[46] A pharmaceutical composition for use in the treatment of cancer, comprising the compound according to any one of [1] to [39] or a pharmaceutically acceptable salt thereof.

[0054]

[47] The compound according to any one of [1] to [39] or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.

20

(EFFECTS OF THE INVENTION)

[0055] The present compound has a potent inhibitory effect on the sphere-forming ability of cancer cells. In addition, the preferred present compound has high bioavailability after oral administration. Thus, the

25

present compound is useful as an orally-available anti-tumor agent.

DESCRIPTION OF EMBODIMENTS

5 [0056] Hereinafter, the present invention is explained in detail. The number of carbon atoms in the definition of the "substituent" used herein may be expressed as, for example, "C₁₋₆". Specifically, the term "C₁₋₆ alkyl" is used for the same meaning as alkyl group having 1 to 6 carbon
10 atoms.

[0057] Specific examples of "halogen atom" used herein include fluorine atom, chlorine atom, bromine atom, and iodine atom.

[0058] The term "C₁₋₆ alkyl group" used herein means a
15 straight or branched, saturated hydrocarbon group having 1 to 6 carbon atoms. Preferred examples thereof include "C₁₋₄ alkyl group". Specific examples of the "C₁₋₆ alkyl group" include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-
20 dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl.

[0059] The term "C₂₋₆ alkenyl group" used herein means a straight or branched, unsaturated hydrocarbon group having 2 to 6 carbon atoms and 1 to 3 carbon-carbon double bonds.
25 Preferred examples thereof include "C₂₋₄ alkenyl group".


Specific examples of the "C₂₋₆ alkenyl group" include ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

[0060] The term "C₂₋₆ alkynyl group" used herein means a straight or branched, unsaturated hydrocarbon group having 2 to 6 carbon atoms and 1 to 3 carbon-carbon triple bonds. Preferred examples thereof include "C₂₋₄ alkynyl group". Specific examples of the "C₂₋₆ alkynyl group" include ethynyl, propynyl, butynyl, penthynyl, and hexynyl.

[0061] The term "C₁₋₄ alkylene group" used herein means a straight or branched, divalent saturated hydrocarbon group having 1 to 4 carbon atoms, or a divalent saturated hydrocarbon group containing a cyclic structure having 3 to 4 carbon atoms.

Specific examples of the straight or branched "C₁₋₄ alkylene group" include methylene, ethylene, trimethylene, tetramethylene, 1-methylmethylene, 1-ethylmethylene, 1-propylmethylene, 1-methylethylene, 2-methylethylene, and 1-ethylethylene. Preferred examples thereof include methylene and ethylene.

Specific examples of the "C₁₋₄ alkylene group" containing a cyclic structure include the following groups:



[0062] The term "C₃₋₄ alkenylene group" used herein means a straight or branched, divalent hydrocarbon group having 3 to 4 carbon atoms and a carbon-carbon double bond. Specific examples of the "C₃₋₄ alkenylene group" include propenylene and butenylene.

[0063] The term "C₃₋₄ alkynylene group" used herein means a straight or branched, divalent hydrocarbon group having 3 to 4 carbon atoms and a carbon-carbon triple bond. Specific examples of the "C₃₋₄ alkynylene group" include propynylene and butynylene.


[0064] The "C₁₋₆ alkyl" moiety of the term "C₁₋₆ alkoxy group" used herein is as defined in the above "C₁₋₆ alkyl". Preferred examples thereof include "C₁₋₄ alkoxy group". Specific examples of the "C₁₋₆ alkoxy group" include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and *tert*-butoxy.

[0065] The term "C₃₋₁₀ cycloalkyl group" used herein means a 3- to 10-membered monocyclic or polycyclic, saturated or partially-unsaturated hydrocarbon group. The group is preferably "C₃₋₇ cycloalkyl group", and more preferably cyclohexyl group. Specific examples of the "C₃₋₁₀ cycloalkyl group" include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, decalinyl, adamantyl, and norbornyl.


[0066] The term "C₆₋₁₀ aryl group" used herein means an

aromatic hydrocarbon group having 6 to 10 carbon atoms. The group is preferably "C₆ aryl group" (phenyl). Specific examples of the "C₆₋₁₀ aryl group" include phenyl, 1-naphthyl, or 2-naphthyl.

5 [0067] Examples of the term "5- to 10-membered heteroaryl group" used herein include a 5- to 10-membered mono- or bi-cyclic aromatic group which contains the same or different one or more (e.g. 1 to 4) heteroatoms selected from the group consisting of nitrogen atom, sulfur atom,
10 and oxygen atom. The bicyclic heteroaryl group also encompasses a fused ring group of a monocyclic heteroaryl group mentioned above with an aromatic group (such as benzene and pyridine) or a non-aromatic ring (such as cyclohexyl and piperidine). Specific examples of the
15 "heteroaryl group" include the groups of the following formulae:




[0068] The bond across a ring in the above formulae means that a "group" is linked at any replaceable position in the ring. For example, when a group is the heteroaryl group of the following formula:



the group means 2-pyridyl group, 3-pyridyl group, or 4-pyridyl group.

[0069] Furthermore, when a "heteroaryl group" is a bicyclic group, for example, the group of the following formula:



the group may be 1-benzimidazolyl, 2-benzimidazolyl, or 4-, 5-, 6- or 7-benzimidazolyl.

[0070] The term "aminocarbonyl group" used herein means
 5 a formyl group wherein hydrogen atom therein is replaced with amino group.

[0071] The "C₁₋₆ alkyl" moiety of the term "C₁₋₆alkyl-carbonylamino group" used herein is as defined in the above "C₁₋₆ alkyl". The group is preferably "C₁₋₄ alkyl-carbonylamino group", and more preferably
 10 methylcarbonylamino group (acetamido group).

[0072] The "C₆₋₁₀ aryl" moiety of the term "C₆₋₁₀ aryloxy group" is as defined in the above "C₆₋₁₀ aryl". Preferred examples thereof include "C₆ aryloxy group" (phenoxy group).

[0073] The "C₁₋₆ alkoxy" moiety of the term "C₁₋₆ alkoxy-carbonyl group" used herein is as defined in the above "C₁₋₆ alkoxy". Preferred examples thereof include "C₁₋₄ alkoxy-carbonyl group". Specific examples of the "C₁₋₆ alkoxy-carbonyl group" include methoxycarbonyl, ethoxycarbonyl,
 15 and propoxycarbonyl.
 20

[0074] The "C₁₋₆ alkyl" moiety of the term "C₁₋₆ alkyl-carbonyl group" used herein is as defined in the above "C₁₋₆ alkyl". Preferred examples thereof include "C₁₋₄ alkyl-

carbonyl group". Specific examples of the "C₁₋₆ alkyl-carbonyl group" include acetyl, ethylcarbonyl, and propylcarbonyl.

[0075] The "C₁₋₆ alkyl" moiety of the term "C₁₋₆ alkylsulfonyl group" used herein is as defined in the above "C₁₋₆ alkyl". Preferred examples thereof include "C₁₋₄ alkylsulfonyl group". Specific examples of the "C₁₋₆ alkylsulfonyl group" include methylsulfonyl, ethylsulfonyl, and propylsulfonyl.

[0076] The "C₁₋₆ alkyl" moiety of the term "C₁₋₆ alkylsulfonylamino group" used herein is as defined in the above "C₁₋₆ alkyl". Preferred examples thereof include "C₁₋₄ alkylsulfonylamino group". Specific examples of the "C₁₋₆ alkylsulfonylamino group" include methylsulfonylamino, ethylsulfonylamino, and propylsulfonylamino.

[0077] The "C₁₋₆ alkoxy" moiety of the term "C₁₋₆alkoxy-carbonylamino group" used herein is as defined in the above "C₁₋₆ alkoxy". Preferred examples thereof include "C₁₋₄ alkoxy-carbonylamino group". Specific examples of the "C₁₋₆ alkoxy-carbonylamino group" include methoxycarbonylamino, ethoxycarbonylamino, and propoxycarbonylamino.

[0078] The term "C₁₋₆ alkyl-carbonyloxy group" used herein means an oxy group substituted with the above "C₁₋₆ alkyl-carbonyl group". Preferred examples thereof include "C₁₋₄ alkyl-carbonyloxy group". Specific examples of the

"C₁₋₆ alkyl-carbonyloxy group" include acetoxy, propionyloxy, and butyryloxy.

[0079] The term "aminosulfonyl group" used herein means a sulfo group wherein hydroxy group therein is substituted with amino group.

[0080] Examples of the substituent in the terms "optionally-substituted C₁₋₆ alkyl group", "optionally-substituted C₂₋₆ alkenyl group", "optionally-substituted C₂₋₆ alkynyl group", "optionally-substituted C₁₋₄ alkylene group", "optionally-substituted C₃₋₄ alkenylene group", "optionally-substituted C₃₋₄ alkynylene group", "optionally-substituted C₁₋₆ alkoxy group", "optionally-substituted C₁₋₆ alkyl-carbonyl group", "optionally-substituted C₁₋₆ alkylsulfonyl group", "optionally-substituted C₁₋₆ alkoxy-carbonyl group", "optionally-substituted C₁₋₆ alkyl-carbonylamino group", "optionally-substituted C₁₋₆ alkylsulfonylamino group", "optionally-substituted C₁₋₆ alkoxy-carbonylamino group", "optionally-substituted C₁₋₆ alkyl-carbonyloxy group" include hydroxy group, halogen atom, C₃₋₇ cycloalkyl group, and C₁₋₆ alkoxy group, and preferably fluorine atom.

[0081] Examples of the substituent in the terms "optionally-substituted C₆₋₁₀ aryl group", "optionally-substituted C₃₋₁₀ cycloalkyl group", "optionally-substituted 5- to 10-membered heteroaryl group", "optionally-substituted 5- or 6-membered cyclic amino group", and "optionally-substituted 5- or 6-membered cyclic aminocarbonyl group" include

- (a) halogen atom,
- (b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

5 (d) cyano,

(e) C₆₋₁₀ aryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy, and

10 (f) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(g) C₆₋₁₀ aryloxy which may be optionally substituted with
15 the same or different 1 to 4 groups independently selected

from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(h) hydroxy,

(i) amino which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups,

(j) aminocarbonyl wherein the amino moiety thereof may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups,

(k) C₁₋₆ alkoxy-carbonyl wherein the alkoxy moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(l) C₁₋₆ alkyl-carbonyl wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(m) C₁₋₆ alkylsulfonyl wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(n) C₁₋₆ alkyl-carbonylamino wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(o) C₁₋₆ alkylsulfonylamino wherein the alkyl moiety

thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(p) C₁₋₆ alkoxy-carbonylamino wherein the alkoxy moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(q) C₁₋₆ alkyl-carbonyloxy wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(r) aminosulfonyl wherein the amino moiety thereof may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups, and

(s) C₃₋₁₀ cycloalkyl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy.

[0082] Examples of the substituent in the terms "optionally-substituted amino group", "optionally-substituted aminocarbonyl group", and "optionally-substituted aminosulfonyl group" include C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy, and

preferably C₁₋₃ alkyl.

[0083] In the present compound of formula (1'), W¹, W², W³, R¹, R², R⁴, R⁵, n, ring Q¹, and ring Q² are preferably those shown below, but the technical scope of the present invention should not be limited to the following compounds.

[0084] W¹ preferably includes C₁₋₄ alkylene group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy. W¹ is more preferably methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with the same or different 1 to 4 halogen atoms; and furthermore preferably methylene group.

[0085] W²-Q² preferably includes -NR^{3a}C(O)-Q², -NR^{3a}C(O)CH₂O-Q², or -C(O)NR^{3a}-Q² wherein R^{3a} is hydrogen atom or C₁₋₆ alkyl group. W²-Q² is more preferably -NHC(O)-Q² or -C(O)NH-Q²; and furthermore preferably -NHC(O)-Q².

[0086] In another embodiment, W²-Q² preferably includes -NR^{3a}C(O)-Q², -NR^{3a}C(O)CH₂O-Q², -C(O)NR^{3a}-Q², or -NR^{3a}C(O)-CH=CH-Q² wherein R^{3a} is hydrogen atom or C₁₋₆ alkyl group. W²-Q² is more preferably -NHC(O)-Q², -C(O)NH-Q², or -NHC(O)-CH=CH-Q²; and furthermore preferably -NHC(O)-Q².

[0087] Preferably, R¹ and R² independently include hydrogen atom, halogen atom, and C₁₋₄ alkyl group which may

be optionally substituted with the same or different 1 to 3 halogen atoms. R^1 and R^2 are more preferably hydrogen atom, chlorine atom, or methyl group; and furthermore preferably hydrogen atom.

5 [0088]

Ring Q^1 preferably includes

(1) C_{6-10} aryl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of

10 (a) halogen atom,

(b) C_{1-6} alkyl which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy,

15 (c) C_{1-6} alkoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy,

(d) cyano,

20 (e) phenyl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C_{1-6} alkyl, and C_{1-6} alkoxy,

25 (f) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 groups

independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(g) phenoxy which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(h) hydroxy,

(i) amino which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups, and

(j) aminocarbonyl wherein the amino moiety thereof may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups,

(2) C₃₋₁₀ cycloalkyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of (a) to (j) defined in the above (1), or

(3) 5- to 10-membered heteroaryl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of (a) to (j) defined in the above (1).

[0089] Ring Q¹ preferably includes

(1) phenyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of

(a) halogen atom,

(b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

5 (c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(d) cyano,

10 (e) phenyl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy, and

(f) 5- or 6-membered heteroaryl which may be optionally
15 substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy, or

(2) pyridyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected
20 from the group consisting of (a) to (f) defined in the above (1).

[0090] Ring Q¹ furthermore preferably includes phenyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from

25 (a) halogen atom,

(b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 halogen atoms.

5 [0091] Ring Q¹ is furthermore preferably phenyl group substituted with the same or different 1 to 3 halogen atoms.

[0092] Ring Q² is preferably pyridyl group, pyrimidyl group, pyridazyl group, pyrazyl group, oxazolyl group, thiazolyl group, isoxazolyl group, isothiazolyl group, 10 quinolinyl group, isoquinolinyl group, quinazolinyl group, or quinoxalinyl group. The ring is more preferably pyridyl group, pyridazyl group, pyrazyl group, oxazolyl group, thiazolyl group, isoxazolyl group, or quinolinyl group; furthermore preferably pyridyl group or pyrazyl group; and 15 most preferably pyridyl group.

[0093] R⁴ preferably includes

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted 20 with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently 25 selected from the group consisting of halogen atom, hydroxy,

and C₁₋₆ alkoxy,

(5) C₃₋₁₀ cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(6) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(7) C₂₋₆ alkynyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

10 (8) cyano group, or

(9) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups.

[0094] R⁴ preferably includes

(1) hydrogen atom,

15 (2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

20 (4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

25 (5) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or

(6) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups.

[0095] R⁴ furthermore preferably includes

(1) hydrogen atom,

5 (2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy, or

10 (4) amino group.

[0096] R⁴ is furthermore preferably methyl group substituted with 1 to 3 fluorine atoms; and most preferably methyl group substituted with 2 fluorine atoms.

[0097] W³ is preferably

15 (1) C₁₋₄ alkylene group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(2) C₃₋₄ alkenylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or

(3) C₃₋₄ alkynylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms.

25 W³ is more preferably methylene group which may be optionally substituted with the same or different 1 to 2

halogen atoms, or ethylene group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy; and furthermore preferably
5 methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms.

Also, the preferred embodiment includes the present compound wherein one or more of ¹H in W³ are replaced with ²H(D) (*i.e.* deuterated form).

10 [0098] R⁵ preferably includes hydroxy group, or C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy. R⁵ is more preferably hydroxy group.

15 [0099] n in the above [1] and m in the above [12] are independently selected from 1, 2, 3, 4, or 5. Preferably, n and m are independently 1, 2, or 3. When the number of the replaceable positions on the ring having the substituent R⁴ or R¹¹ is less than 5, n and m are
20 independently selected from the maximum replaceable number of R⁴ or R¹¹. For example, when ring Q¹ is pyridyl group, m is selected from 1, 2, 3, or 4.

[0100] The present compound may be in the forms of a hydrate and/or a solvate. Thus, the present compound also
25 encompasses hydrate and/or solvate such as ethanol solvate.

Furthermore, the present compound encompasses all types of crystal forms of the present compound.

Specific examples of the pharmaceutically acceptable salt of the compound of formula (1') include an inorganic acid salt such as hydrochloride, hydrobromide, sulfate, phosphate, and nitrate; and an organic acid salt such as acetate, propionate, oxalate, succinate, lactate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, p-toluenesulfonate, benzenesulfonate, and ascorbate.

10 [0101] The compound of formula (1') may be in the form of a tautomer. Thus, the present compound also encompasses the tautomer of the compound of formula (1').

[0102] The compound of formula (1') may contain one or more asymmetric carbon atoms. Thus, the present compound encompasses not only racemic forms of the compound of formula (1') but also optically-active forms thereof. When the compound of formula (1') contains two or more asymmetric carbon atoms, the compound can result in various stereoisomerisms. Thus, the present compound also encompasses the stereoisomer of the compound and a mixture or isolate thereof.

Also, the compound of formula (1') encompasses the compound wherein one or more of ^1H are replaced with $^2\text{H(D)}$ (*i.e.* deuterated form).

25 [0103] Preparations

The present compounds can be prepared according to processes shown below and according to the processes in combination with known compounds and known synthesis processes.

5 As appropriate, each compound used as a starting compound may be used in the salt form. The shown processes are just examples to prepare the compounds, and may be optionally modified by those skilled in the organic synthesis field.

10 [0104] In each process shown below, any functional groups which need to be protected may be optionally protected and then deprotected after the reaction or reactions are completed to give the desired compound even though the use of protective groups is not specifically
15 described.

 [0105] The protective group used herein includes any conventional groups described in various literatures, for example, T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 3rd Ed., John Wiley and Sons, inc.,
20 New York (1999). In more detail, specific examples of the protective groups for amino group include benzyloxycarbonyl, *tert*-butoxycarbonyl, acetyl, and benzyl, and specific examples of the protective groups for hydroxy group include trialkylsilyl, acetyl, and benzyl.


25 [0106] The protective groups can be introduced and

cleaved according to commonly-used methods in synthetic organic chemistry (e.g. the method described in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 3rd Ed., John Wiley and Sons, inc., New York (1999)) and similar methods thereto.

[0107]


Preparation 1

One of the compounds of formula (1'), the compound of formula (1-7) is prepared by linking each fragment in positions a and b, respectively:



wherein W^1 , W^3 , R^1 , R^2 , R^4 , R^5 , n , ring Q^1 , and ring Q^2 are as defined in the above [1].

[0108] The processes for forming each bond in positions a and b can be illustrated as follows, but the order of procedure for forming each bond may be optionally changed:



wherein W^1 , W^3 , R^1 , R^2 , R^4 , R^5 , n , ring Q^1 , and ring Q^2 are as defined in the above [1]; R^{101} is C_{1-6} alkyl group; L is a leaving group (such as iodine atom, bromine atom, chlorine atom, and substituted sulfonyl group (e.g. methanesulfonyl group and p-toluenesulfonyl group)).

[0109] Compound (1-1) may be a commercially available product or be prepared according to known synthesis processes (e.g. New Version of Heterocyclic Compound (advanced level) edited by Kodansha Scientific Ltd.).

[0110]

Step 1-1: Preparation process of compound (1-2)

Compound (1-2) is prepared by hydrolyzing compound (1-1) according to a similar process to a known process (e.g. Protective Groups in Organic Synthesis 3rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, by R. C. Larock, VCH publisher Inc., 1989).

[0111]

Step 1-2: Preparation process of compound (1-5)

Compound (1-5) is prepared by the alkylation reaction of compounds (1-3) and (1-4) in an inert solvent in the presence of a base.

[0112] Specific examples of the base include an organic base such as triethylamine, diisopropylethylamine, and pyridine; an inorganic base such as potassium carbonate, sodium carbonate, cesium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, potassium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and a metal alkoxide such as sodium methoxide and potassium *tert*-butoxide.

[0113] Specific examples of the inert solvent include a halogenated hydrocarbon such as chloroform and dichloromethane; an aromatic hydrocarbon such as toluene; an ether-type solvent such as diethyl ether, tetrahydrofuran (THF), and 1,4-dioxane; an aprotic polar solvent such as acetonitrile, acetone, methyl ethyl ketone, *N,N*-dimethylformamide, *N*-methyl-2-pyrrolidinone, and dimethylsulfoxide; a basic solvent such as pyridine; and a mixture thereof.

[0114] The reaction temperature is typically 0°C to

150°C, preferably 20°C to 100°C, but is not limited thereto. The reaction time is typically 30 minutes to 48 hours, preferably 30 minutes to 10 hours.

[0115]

5 Step 1-3: Preparation process of compound (1-6)

Compound (1-6) is prepared by reducing the nitro group in compound (1-5). For example, reductions under an acidic condition with a metal such as zinc, iron, and tin or a metal salt such as tin (II) chloride; reductions with a sulfide such as sodium hypodisulfite ($\text{Na}_2\text{S}_2\text{O}_4$); and catalytic hydrogenations with a metal catalyst such as palladium/carbon, Raney nickel, platinum oxide/carbon, and rhodium/carbon under hydrogen atmosphere may be used.

[0116] In the reduction with a metal or a metal salt, the amount of the metal or metal salt to be used is typically about 1 mole to 100 moles, preferably about 10 moles to 30 moles per mole of compound (1-5). Also, the amount of the acid to be used is typically about 1 mole to 100 moles, preferably about 10 moles to 30 moles per mole of compound (1-5). The reduction is typically carried out in a solvent which has no negative effect on the reaction (e.g. ethanol). The reaction temperature is typically 0°C to 100°C, but is not limited thereto. The reaction time is typically 30 minutes to 8 hours.

[0117] In the catalytic hydrogenation reaction, the

amount of the metal catalyst to be used for compound (1-5) is typically 0.1% by weight to 1000% by weight, preferably 1% by weight to 100% by weight. The reaction may be carried out in a solvent such as an alcohol such as methanol; an ether such as tetrahydrofuran; and an ester such as ethyl acetate. The hydrogen pressure is typically 1 atm to 100 atms, preferably 1 atm to 5 atms. The reaction temperature is typically 0°C to 120°C, preferably 20°C to 80°C, but is not limited thereto. The reaction time is typically 30 minutes to 72 hours, preferably 1 hour to 48 hours.

[0118] Also, the reaction may be carried out in the presence of an acid catalyst, as appropriate. For example, an organic acid such as formic acid, acetic acid, and trifluoroacetic acid, and an inorganic acid such as sulfuric acid, hydrochloric acid, and hydrobromic acid are used as the acid catalyst. The amount of the acid to be used is 0.1 mole or more per mole of compound (1-5).

[0119]

20 Step 1-4: Preparation process of compound (1-7)

Compound (1-7) is prepared by reacting compound (1-2) with compound (1-6) in an inert solvent in the presence of a condensation agent.

[0120] The reaction may be carried out in the presence of a base, as appropriate. The reaction temperature is

typically about -20°C to the boiling point of the used solvent, but is not limited thereto. The reaction time is typically 10 minutes to 48 hours, which may vary according to various conditions such as a reaction temperature, a
5 condensation agent, a starting material, and a solvent to be used.

[0121] Specific examples of the condensation agent include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3-(3-
10 dimethylaminopropyl)-carbodiimide (WSC), benzotriazol-1-yl-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), diphenylphosphoryl azide (DPPA), N,N-carbonyldiimidazole (CDI), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-
15 N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and diphenyl chlorophosphate. As appropriate, the reaction may be carried out with the addition of an additive such as N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), and 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine
20 (HOOBt).

[0122] Specific examples of the base include an organic base such as triethylamine, diisopropylethylamine, and pyridine; an inorganic base such as potassium carbonate, sodium carbonate, cesium carbonate, potassium hydrogen
25 carbonate, sodium hydrogen carbonate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, potassium

phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and a metal alkoxide such as sodium methoxide and potassium *tert*-butoxide.


5 [0123] Specific example of the inert solvent include a halogenated hydrocarbon such as chloroform and dichloromethane; an aromatic hydrocarbon such as toluene; an ether-type solvent such as diethyl ether, tetrahydrofuran (THF), and 1,4-dioxane; an aprotic polar
10 solvent such as acetonitrile, acetone, methyl ethyl ketone, dimethylformamide, N-methyl-2-pyrrolidinone, and dimethylsulfoxide; a basic solvent such as pyridine; and a mixture thereof.

[0124] Compound (1-7) is also prepared by reacting an
15 acid halide or an acid anhydride derived from compound (1-2) with compound (1-6) in an inert solvent in the presence of a base.

[0125]

Preparation 2

20 In the compounds of formula (1-1), the compounds of formulae (2-5), (2-8), (2-11), and (2-13) are prepared according to, for example, the following process.



wherein R^4 , n , and ring Q^2 are as defined in the above [1];
 A is boronic acid or boronate; R^{101} is C_{1-6} alkyl group; R^{102}
 is optionally-substituted C_{1-6} alkyl group; R^a and R^b are
 5 independently the same or different hydrogen atom or methyl
 group; R is benzenesulfonyl group substituted with one or
 two nitro groups; X is halogen atom, and L is a leaving
 group (such as iodine atom, bromine atom, chlorine atom,
 and substituted sulfonyl group (e.g. methanesulfonyl group
 and p-toluenesulfonyl group)).

[0126]

Step 2-1: Preparation process of compound (2-3)

Compound (2-3) is prepared by reacting compound (2-1) with compound (2-2) in an inert solvent in the presence of a palladium catalyst and a base.

5 [0127] Specific examples of the palladium catalyst include tetrakis(triphenylphosphine)palladium (0), bis(dibenzylideneacetone)palladium (0), tris(dibenzylideneacetone)dipalladium (0), bis(tri-tert-butylphosphine)palladium (0), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride.

Specific examples of the base include an inorganic base such as potassium carbonate, sodium carbonate, cesium carbonate, potassium phosphate, potassium hydroxide, and sodium hydroxide.

15 Specific examples of the inert solvent include toluene, 1,2-dimethoxyethane, 1,4-dioxane, DMF, water, and a mixture thereof.

The reaction temperature is typically 50°C to 150°C, preferably 80°C to 120°C, but is not limited thereto. Also, 20 the reaction may be carried out under microwave irradiation. The reaction time is typically 1 hour to 24 hours, preferably 2 hours to 12 hours.

[0128]

Step 2-2: Preparation process of compound (2-4)

25 Compound (2-4) is prepared by reacting compound (2-3)

with osmium tetroxide or potassium osmate (IV) dihydrate in the presence of sodium periodate.

[0129] Examples of the solvent used include acetone, 1,4-dioxane, THF, *tert*-butanol, water, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 25°C to 50°C, but is not limited thereto. The reaction time is typically 1 hour to 72 hours, preferably 1 hour to 24 hours.

[0130] Also, compound (2-4) is prepared by treating compound (2-3) with oxygen currents including ozone and then reacting the treated compound with a reducing agent such as dimethyl sulfide in a solvent such as dichloromethane, ethyl acetate, and methanol. The reaction temperature is typically -78°C to room temperature, but is not limited thereto. The reaction time is typically 1 hour to 72 hours, preferably 6 hours to 24 hours.

[0131]

Step 2-3: Preparation process of compound (2-5)

Compound (2-5) is prepared by reacting compound (2-4) with an organometallic reagent or a hydride reducing agent.

[0132] Specific examples of the organometallic reagent include methyllithium reagent and methyl Grignard reagent.

Specific examples of the hydride reducing agent include sodium borohydride and sodium cyanoborohydride.

[0133] The solvent used in the reaction with the organometallic reagent includes THF, diethyl ether, and a mixture thereof, and the solvent used in the reaction with the hydride reducing agent includes methanol, ethanol,
5 dichloromethane, toluene, and a mixture thereof.

The reaction temperature is typically -78°C to 50°C , preferably 0°C to 25°C , but is not limited thereto. The reaction time is typically 5 minutes to 12 hours, preferably 30 minutes to 6 hours.

10 [0134]

Step 2-4: Preparation process of compound (2-6)

Compound (2-6) wherein L is substituted sulfonyl group is prepared by reacting compound (2-5) with an alkyl- or aryl-sulfonyl chloride in an inert solvent in the presence
15 of a base.

[0135] Specific examples of the alkyl- or aryl-sulfonyl chloride include methanesulfonyl chloride, benzenesulfonyl chloride, p-toluenesulfonyl chloride, and 2,4,6-trimethylbenzene chloride.

20 Examples of the base include an organic base such as triethylamine, diisopropylethylamine, and pyridine; potassium carbonate, sodium carbonate, cesium carbonate, potassium hydrogen carbonate, and sodium hydrogen carbonate.

Examples of the inert solvent include THF,
25 dichloromethane, toluene, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 1 hour to 72 hours, preferably 1 hour to 24 hours.

5 [0136] Compound (2-6) wherein L is halogen is prepared by reacting compound (2-5) with a halogenating agent or alkyl- or aryl-sulfonyl chloride and an alkali metal halide in an inert solvent.

[0137] Examples of the halogenating agent include
10 thionyl chloride, oxalyl dichloride, phosphorus tribromide, phosphorus pentabromide, and phosphorus oxychloride.

Specific examples of the alkyl- or aryl-sulfonyl chloride include methanesulfonyl chloride, benzenesulfonyl chloride, p-toluenesulfonyl chloride, and 2,4,6-
15 trimethylbenzenesulfonyl chloride, and examples of the alkali metal halide include lithium chloride, sodium chloride, potassium chloride, lithium bromide, sodium bromide, potassium bromide, lithium iodide, sodium iodide, and potassium iodide.

20 [0138]

Step 2-5: Preparation process of compound (2-8)

Compound (2-8) is prepared by reacting compound (2-6) with sodium alkoxide of formula (2-7). As appropriate, sodium alkoxide may be prepared from sodium metal and
25 various alcohols.

[0139] Examples of the solvent used include methanol, ethanol, THF, DMF, 1,4-dioxane, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The
5 reaction time is typically 30 minutes to 12 hours, preferably 1 hour to 6 hours.

[0140]

Step 2-6: Preparation process of compound (2-10)

Compound (2-10) is prepared by the Mitsunobu reaction
10 of compound (2-5) and benzenesulfonamide of formula (2-9) in an inert solvent in the presence of a Mitsunobu reagent.

[0141] Examples of the Mitsunobu reagent include diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), triphenylphosphine, and tributylphosphine. Also,
15 cyanomethylenetrimethylphosphorane (Tsunoda Reagent) may be used.

Examples of the inert solvent include toluene, benzene, THF, 1,4-dioxane, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C,
20 preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 1 hour to 48 hours, preferably 12 hours to 24 hours.

[0142]

Step 2-7: Preparation process of compound (2-11)

25 Compound (2-11) is prepared by reacting compound (2-

10) with a thiol in the presence of a base and cleaving benzenesulfonyl group.

Examples of the thiol include thiophenol and dodecanethiol.

5 Examples of the base include an inorganic base such as cesium carbonate and potassium carbonate.

The solvent used includes DMF, toluene, THF, 1,4-dioxane, and a mixture thereof.

10 The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 1 hour to 48 hours, preferably 3 hours to 12 hours.

[0143]

Step 2-8: Preparation process of compound (2-12)

15 Compound (2-12) is prepared by reacting compound (2-6) with di-*tert*-butyl iminodicarboxylate in an inert solvent in the presence of a base.

[0144] Examples of the base include sodium hydride, potassium *tert*-butoxide, sodium bis(trimethylsilyl)amide, 20 lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, and lithium diisopropylamide.

Examples of the inert solvent include DMF, THF, and a mixture thereof.

25 The reaction temperature is typically 0°C to 150°C, preferably 25°C to 120°C, but is not limited thereto. The

reaction time is typically 1 hour to 72 hours, preferably 6 hours to 24 hours.

[0145]

Step 2-9: Preparation process of compound (2-13)

5 Compound (2-13) is prepared by cleaving Boc group in compound (2-12) under an acidic condition and then treating the resulting amine with an acylating agent in an inert solvent in the presence of a base.

[0146] Examples of the acid used in the deprotection
10 step include trifluoroacetic acid, hydrochloric acid, and sulfuric acid.

 The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 1 hour to 72 hours, preferably 6
15 hours to 24 hours.

[0147] The acylating agent includes carboxylic halide such as $R^{102}COCl$ and $R^{102}COBr$; and carboxylic anhydride such as $(R^{102}CO)_2O$. As appropriate, a promoter such as DMAP may be used.

20 Examples of the base include an organic base such as triethylamine, diisopropylethylamine, and pyridine; potassium carbonate, sodium carbonate, cesium carbonate, potassium hydrogen carbonate, and sodium hydrogen carbonate.

 Examples of the inert solvent include dichloromethane,
25 1,2-dichloroethane, THF, toluene, ethyl acetate, and a


mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 30 minutes to 12 hours, preferably 1 hour to 6 hours.

[0148]

Preparation 3

One of the compounds of formula (2-1), the compound of formula (3-5) is prepared according to, for example, the following process.



wherein ring Q^2 is as defined in the above [1]; R^{101} is C_{1-6} alkyl group; X is halogen atom; and Y is bromine atom or iodine atom.

[0149]

Step 3-1: Preparation process of compound (3-2)

Compound (3-2) is prepared by reacting compound (3-1) with a brominating agent in an inert solvent in the presence of a radical initiator.

[0150] Specific examples of the radical initiator include azobisisobutyronitrile (AIBN) and benzoyl peroxide (BPO).

Specific examples of the brominating agent include N-
5 bromosuccinimide and bromine.

Examples of the inert solvent include carbon tetrachloride, chlorobenzene, and a mixture thereof.

The reaction temperature is typically 50°C to 150°C, preferably 80°C to 120°C, but is not limited thereto. The
10 reaction time is typically 3 hours to 48 hours, preferably 4 hours to 12 hours.

[0151]

Step 3-2: Preparation process of compound (3-4)

Compound (3-4) is prepared by reacting compound (3-2)
15 with silver nitrate in an inert solvent.

[0152] Specific examples of the inert solvent include acetonitrile, THF, 1,4-dioxane, and a mixture thereof.

The reaction temperature is typically 50°C to 150°C, preferably 80°C to 120°C, but is not limited thereto. The
20 reaction time is typically 3 hours to 48 hours, preferably 4 hours to 12 hours.

[0153]

Step 3-3: Preparation process of compound (3-4)

Compound (3-4) is also prepared by reacting compound
25 (3-3) with an organometallic reagent and then treating the

resulting compound with a formylating agent.

Examples of the organometallic reagent include isopropylmagnesium chloride-lithium chloride complex, isopropylmagnesium chloride, and n-butyllithium.

5 Examples of the solvent used include THF, diethyl ether, toluene, and a mixture thereof.

Examples of the formylating agent include DMF and N-formylmorpholine.

10 The reaction temperature is typically -78°C to 50°C, preferably -30°C to 25°C, but is not limited thereto. The reaction time is typically 30 minutes to 24 hours, preferably 1 hour to 6 hours.

[0154]

Step 3-4: Preparation process of compound (3-5)

15 Compound (3-5) is prepared by reacting compound (3-4) with a deoxofluorinating agent in an inert solvent.

Specific examples of the deoxofluorinating agent include diethylaminosulfur trifluoride (DAST), bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor[®]),
20 XtalFluor-E[®], XtalFluor-M[®], and 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride (Fluolead[®]). As appropriate, compounds such as DBU, triethylamine trihydrofluoride, and triethylamine dihydrofluoride may be used as a promoter.

25 Specific examples of the inert solvent include

dichloromethane, 1,2-dichloroethane, toluene, THF, and a mixture thereof.


The reaction temperature is typically -20°C to 50°C, preferably 0°C to 25°C, but is not limited thereto. The reaction time is typically 10 minutes to 12 hours, preferably 30 minutes to 3 hours.

[0155] Compound (3-5) is also prepared by reacting compound (3-4) with sulfur tetrafluoride.

[0156]

10 Preparation 4

One of the compounds of formula (1-1), the compound of formula (4-3) is prepared according to, for example, the following process.



15 wherein R^4 , n , and ring Q^2 are as defined in the above [1];
and R^{101} is C_{1-6} alkyl group.

[0157]

Step 4-1: Preparation process of compound (4-2)

Compound (4-2) is prepared by hydrobrominating
20 compound (4-1) with a brominating agent in an inert solvent
and then treating the resulting compound with a base.

[0158] Examples of the brominating agent used in the hydrobromination step include N-bromosuccinimide.

Examples of the inert solvent include *tert*-butanol, water, THF, 1,4-dioxane, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The
5 reaction time is typically 30 minutes to 12 hours, preferably 1 hour to 6 hours.

[0159] Examples of the base used in the treatment step include sodium hydride, potassium hydride, NaHMDS, potassium-*tert*-butoxide, sodium hydroxide, potassium
10 hydroxide, and triethylamine.

Examples of the inert solvent include THF, 1,4-dioxane, DMF, and a mixture thereof.

The reaction temperature is typically 0°C to 80°C, preferably 0°C to 50°C, but is not limited thereto. The
15 reaction time is typically 30 minutes to 8 hours, preferably 1 hour to 4 hours.

[0160]

Step 4-2: Preparation process of compound (4-3)

Compound (4-3) is prepared by hydrogenating compound
20 (4-2) with a palladium catalyst in an inert solvent.

[0161] Examples of the palladium catalyst include palladium-carbon and palladium hydroxide.

Examples of the solvent used include THF, methanol, ethanol, 2-propanol, and a mixture thereof.


25 The reaction temperature is typically 0°C to 100°C,

preferably 25°C to 80°C, but is not limited thereto. The reaction time is typically 1 hour to 12 hours, preferably 2 hours to 6 hours.

[0162]

5 Preparation 5

One of the compounds of formula (1-1), the compound of formula (5-1) is prepared according to, for example, the following process.



10 wherein R^4 , n , and ring Q^2 are as defined in the above [1];
and R^{101} is C_{1-6} alkyl group.

[0163] Compound (5-1) is prepared by reacting compound (4-1) with osmium tetroxide in an appropriate solvent in the presence of N-methylmorpholine-N-oxide.


15 [0164] Examples of the solvent used include acetone,
1,4-dioxane, THF, *tert*-butanol, water, and a mixture
thereof.

The reaction temperature is typically 0°C to 100°C, preferably 25°C to 50°C, but is not limited thereto. The reaction time is typically 1 hour to 72 hours, preferably 6 hours to 24 hours.

[0165]

Preparation 6

One of the compounds of formula (1-1), the compound of formula (6-2) is prepared according to, for example, the following process.



wherein R^4 , n , and ring Q^2 are as defined in the above [1]; and R^{101} is C_{1-6} alkyl group.

[0166] Compound (6-2) is prepared by reacting compound (6-1) with paraformaldehyde under microwave irradiation with heating in the presence of a base.

[0167] Examples of the base include N,N -diisopropylethylamine, triethylamine, pyridine, and DBU.

Examples of the solvent used include water, THF, 1,4-dioxane, and a mixture thereof.


15 The reaction temperature is typically 100°C to 200°C , preferably 120°C to 180°C , but is not limited thereto. The reaction time is typically 30 minutes to 12 hours, preferably 1 hour to 6 hours.

[0168]

20 Preparation 7

One of the compounds of formula (1-1), the compound of formula (7-2) is prepared according to, for example, the

following process.



wherein R^4 , n , and ring Q^2 are as defined in the above [1]; and R^{101} is C_{1-6} alkyl group.

5 [0169] Compound (7-2) is prepared by reacting compound (7-1) with a carboxylic acid chloride in the presence of a base to convert the compound to an acid anhydride, and then reducing the resulting acid anhydride with a hydride reducing agent.

10 [0170] Examples of the base used in the step for producing the acid anhydride include N-methylmorpholine, N,N-diisopropylethylamine, triethylamine, pyridine, and DBU.

Specific examples of the carboxylic acid chloride include isobutyl chloroformate, ethyl chloroformate, methyl
15 chloroformate, and acetyl chloride.

Examples of the solvent used include DME, THF, 1,4-dioxane, dichloromethane, 1,2-dichloroethane, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C ,
20 preferably 0°C to 25°C , but is not limited thereto. The reaction time is typically 30 minutes to 12 hours, preferably 1 hour to 6 hours.

[0171] Specific examples of the hydride reducing agent used in the reduction step include sodium borohydride and sodium triacetoxyborohydride.


Examples of the solvent used include methanol, ethanol,
5 2-propanol, and THF.

The reaction temperature is typically 0°C to 50°C, preferably 0°C to 25°C, but is not limited thereto. The reaction time is typically 30 minutes to 12 hours, preferably 1 hour to 6 hours.

10 [0172]

Preparation 8

One of the compounds of formula (1'), the compound of formula (8-3) is prepared according to, for example, the following process.



15

wherein W^1 , R^1 , R^2 , R^4 , n , ring Q^1 , and ring Q^2 are as defined in the above [1]; R^{101} is C_{1-6} alkyl group; and R^c

and R^d are independently the same or different hydrogen atom, deuterium atom, or methyl group.

[0173]

Step 8-1: Preparation process of compound (8-2)

5 Compound (8-2) is prepared from compounds (8-1) and (1-6) according to the process of Step 1-4.

[0174]

Step 8-2: Preparation process of compound (8-3)

10 Compound (8-3) is prepared by reacting compound (8-2) with an organometallic reagent or a hydride reducing agent in an inert solvent.

[0175] Specific examples of the organometallic reagent include methyllithium reagent and methyl Grignard reagent. Examples of the solvent used include THF, diethyl ether, and a mixture thereof.

[0176] Specific examples of the hydride reducing agent include sodium borohydride, lithium borohydride, lithium aluminum hydride, sodium cyanoborohydride, lithium triethylborohydride, diisobutylaluminium hydride, sodium bis(2-methoxyethoxy)aluminium hydride, lithium borodeuteride, and lithium aluminum deuteride. Examples of the solvent used include methanol, ethanol, dichloromethane, toluene, and a mixture thereof.


[0177] The reaction temperature is typically -78°C to 25°C, preferably 0°C to 25°C, but is not limited thereto.

The reaction time is typically 5 minutes to 12 hours, preferably 30 minutes to 6 hours.

[0178]

Preparation 9

5 In the compounds of formula (1'), the compounds of formulae (9-2), (9-3), and (9-4) are prepared according to, for example, the following process.



10 wherein W^1 , R^1 , R^2 , ring Q^1 , and ring Q^2 are as defined in the above [1]; X is halogen atom; and R^c and R^d are independently the same or different hydrogen atom, deuterium atom, or methyl group.

[0179]

Step 9-1: Preparation process of compound (9-2)

15 Compound (9-2) is prepared by the palladium-catalyzed cross-coupling reaction of compound (9-1) with various coupling reagents in an inert solvent.

[0180] Specific examples of the coupling reagent include

methylchlorozinc, methylbromozinc, methyliodozinc, methylboronic acid, methylboronic acid pinacol ester, and methyltrifluoroborane-potassium salt.

5 Examples of the inert solvent include THF, toluene, 1,2-dimethoxyethane, 1,4-dioxane, DMF, and a mixture thereof. Specific examples of the palladium reagent include tetrakis(triphenylphosphine)palladium (0), bis(dibenzylideneacetone)palladium (0), tris(dibenzylideneacetone)dipalladium (0), bis(tri-tert-
10 butylphosphine)palladium (0), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride.

Specific examples of the base include an inorganic base such as potassium carbonate, sodium carbonate, cesium carbonate, potassium phosphate, potassium hydroxide, and
15 sodium hydroxide.

The reaction temperature is typically 0°C to 150°C, preferably 25°C to 100°C, but is not limited thereto. The reaction time is typically 1 hour to 72 hours, preferably 1 hour to 24 hours.

20 [0181]

Step 9-2: Preparation process of compound (9-3)

Compound (9-3) is prepared from compound (9-1) according to the process of Step 2-1.

[0182]

25 Step 9-3: Preparation process of compound (9-4)

Compound (9-4) is prepared by hydrogenating vinyl group in compound (9-3) with a metal catalyst in an appropriate solvent.

[0183] Examples of the metal catalyst include
5 palladium/carbon, Raney nickel, platinum oxide/carbon, and rhodium/carbon.

The amount of the metal catalyst to be used for compound (9-2) is typically 0.1% by weight to 1000% by weight, preferably 1% by weight to 100% by weight.

10 Examples of the solvent include an alcohol such as methanol; an ether such as tetrahydrofuran; and an ester such as ethyl acetate.

The hydrogen pressure is typically 1 atm to 100 atms, preferably 1 atm to 5 atms.


15 The reaction temperature is typically 0°C to 120°C, preferably 20°C to 80°C, but is not limited thereto. The reaction time is typically 30 minutes to 72 hours, preferably 1 hour to 48 hours.

[0184] Compound (9-4) is also prepared by reacting
20 compound (9-3) with hydrazine hydrate.

[0185]

Preparation 10

One of the compounds of formula (1'), the compound of formula (10-4) is prepared according to, for example, the
25 following process.



wherein W^1 , R^1 , R^2 , and ring Q^1 are as defined in the above [1]; X^1 and X^2 are as defined in the above [25]; R^{101} is C_{1-6} alkyl group, R^{102} is C_{1-6} alkyl group, benzyl group, and allyl group; and R^a and R^b are independently the same or different hydrogen atom or methyl group.

[0186] Compound (10-1) may be prepared according to, for example, the process of Preparation 2.

[0187]

10 Step 10-1: Preparation process of compound (10-2)

Compound (10-2) is prepared by reacting compound (10-1) with an aqueous alkaline solution.

[0188] Examples of the aqueous alkaline solution include aqueous sodium hydroxide solution, aqueous potassium hydroxide solution, and aqueous lithium hydroxide solution, and the concentration thereof is typically 1-10 mol/L, preferably 1-5 mol/L.

Examples of the solvent used include methanol, ethanol,

2-propanol, THF, 1,4-dioxane, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 10 minutes to 24 hours, preferably 30 minutes to 12 hours.

[0189]

Step 10-2: Preparation process of compound (10-3)

Compound (10-3) is prepared from compounds (10-2) and (1-6) according to the process of Step 1-4.

[0190]

Step 10-3: Preparation process of compound (10-4)

Compound (10-4) is prepared by reacting compound (10-3) with an aqueous alkaline solution.

[0191] Examples of the aqueous alkaline solution include aqueous sodium hydroxide solution, aqueous potassium hydroxide solution, and aqueous lithium hydroxide solution, and the concentration thereof is typically 1-10 mol/L, preferably 1-5 mol/L.


Examples of the solvent used include methanol, ethanol, 2-propanol, THF, 1,4-dioxane, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 1 hour to 24 hours, preferably 1 hour to 6 hours.

[0192]

Preparation 11

One of the compounds of formula (1'), the compound of formula (11-4) is prepared according to, for example, the following process.



wherein W^1 , W^3 , R^1 , R^2 , R^4 , R^5 , n , ring Q^1 , and ring Q^2 are as defined in the above [1]; and R^{101} is C_{1-6} alkyl group.

[0193] Compound (11-1) may be a commercially available product or be prepared according to known synthesis processes (e.g. WO 2014/125444).

[0194]

Step 11-1: Preparation process of compound (11-2)

Compound (11-2) is prepared by hydrolyzing compound (11-1) according to a similar process to a known process (e.g. Protective Groups in Organic Synthesis 3rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, by R. C. Larock, VCH publisher Inc., 1989).

[0195]


Step 11-2: Preparation process of compound (11-4)

Compound (11-4) is prepared from compounds (11-2) and (11-3) according to the process of Step 1-4.

[0196]

Preparation 12

5 One of the compounds of formula (1'), the compound of formula (12-5) is prepared according to, for example, the following process.



10 wherein W^1 , R^1 , R^2 , R^4 , n , ring Q^1 , and ring Q^2 are as defined in the above [1]; R^{101} is C_{1-6} alkyl group; and R^c and R^d are independently the same or different hydrogen atom, deuterium atom, or methyl group.

[0197]

Step 12-1: Preparation process of compound (12-2)

15 Compound (12-2) is prepared by reacting compound (12-1) with haloacetate in an inert solvent in the presence of a base.

[0198] Specific examples of the haloacetate include *tert*-butyl chloroacetate, *tert*-butyl bromoacetate, and *tert*-butyl iodoacetate.

Examples of the base include potassium carbonate, sodium carbonate, cesium carbonate, potassium *tert*-butoxide, sodium hydride, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, and lithium diisopropylamide.

Examples of the inert solvent include DMF, THF, acetonitrile, and a mixture thereof.

The reaction temperature is typically 25°C to 150°C, preferably 70°C to 100°C, but is not limited thereto. The reaction time is typically 10 minutes to 12 hours, preferably 20 minutes to 6 hours.

[0199]

Step 12-2: Preparation process of compound (12-3)

Compound (12-3) is prepared by cleaving *tert*-butylester group in compound (12-2) under an acid condition.

Examples of the acid used in the deprotection step include hydrochloric acid, sulfuric acid, HBr, HI, and TFA.

Examples of the solvent used include methanol, ethanol, dichloromethane, 1,2-dichloroethane, THF, 1,4-dioxane, ethyl acetate, a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 25°C to 50°C, but is not limited thereto. The

reaction time is typically 1 hour to 24 hours, preferably 2 hours to 12 hours.

[0200]

Step 12-3: Preparation process of compound (12-4)

5 Compound (12-4) is prepared from compounds (12-3) and (1-6) according to the process of Step 1-4.

[0201]


Step 12-4: Preparation process of compound (12-5)

10 Compound (12-5) is prepared from compound (12-4) according to the process of Step 8-2.

[0202]

Preparation 13

15 The compound of formula (2-5) is also prepared from compound (2-1) according to, for example, the following process.



wherein R^4 , n , and ring Q^2 are as defined in the above [1]; R^{101} is C_{1-6} alkyl group; R^a and R^b are independently the same or different hydrogen atom or methyl group; A is

boronic acid, boronate, BF_3K , or BF_3Na ; R^{103} is optionally-substituted phenyl group; and X is halogen atom.

[0203]

Step 13-1: Preparation process of compound (13-2)

5 Compound (13-2) is prepared by reacting compound (2-1) with compound (13-1) in an inert solvent in the presence of a palladium catalyst and a base.

[0204] Examples of the palladium catalyst include
 tetrakis(triphenylphosphine)palladium (0),
 10 bis(dibenzylideneacetone)palladium (0),
 tris(dibenzylideneacetone)dipalladium (0), bis(tri-tert-butylphosphine)palladium (0), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride.

15 Examples of the base include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, and potassium hydroxide.

Examples of the inert solvent include 1,4-dioxane, THF, 1,2-dimethoxyethane, water, and a mixture thereof.

20 The reaction temperature is typically 50°C to 200°C , preferably 80°C to 150°C , but is not limited thereto. The reaction time is typically 1 hour to 48 hours, preferably 6 hours to 18 hours.

[0205]

Step 13-2: Preparation process of compound (2-5)

25 Compound (2-5) is prepared by hydrogenating benzyl

group in compound (13-2) with a metal catalyst in an appropriate solvent to cleave the group.

[0206] Examples of the metal catalyst include palladium/carbon, Raney nickel, platinum oxide/carbon, and
5 rhodium/carbon.

The amount of the metal catalyst to be used for compound (13-2) is typically 0.1% by weight to 1000% by weight, preferably 1% by weight to 100% by weight.

Examples of the solvent include an alcohol such as
10 methanol; an ether such as tetrahydrofuran; and an ester such as ethyl acetate.

The hydrogen pressure is typically 1 atm to 100 atms, preferably 1 atm to 5 atms.

The reaction temperature is typically 0°C to 120°C,
15 preferably 20°C to 80°C, but is not limited thereto. The reaction time is typically 30 minutes to 72 hours, preferably 1 hour to 48 hours.

[0207] Also, when R^{103} is phenyl group substituted with group(s) such as 4-methoxy group and 2,4-dimethoxy group,
20 compound (2-5) is prepared by reacting compound (13-2) with an acid.

[0208] Examples of the acid include TFA, formic acid, hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, methanesulfonic acid, and ($\pm$) 10-camphorsulfonic acid.

25 Examples of the solvent used include dichloromethane,


1,2-dichloroethane, 1,4-dioxane, THF, toluene, ethyl acetate, methanol, ethanol, 2-propanol, and a mixture thereof.

The reaction temperature is typically 0°C to 100°C, preferably 25°C to 50°C, but is not limited thereto. The reaction time is typically 30 minutes to 12 hours, preferably 1 hour to 9 hours.

[0209]

Preparation 14

One of the compounds of formula (1'), the compound of formula (14-3) is prepared according to, for example, the following process.



wherein W^1 , R^1 , R^2 , R^4 , n , ring Q^1 , and ring Q^2 are as defined in the above [1]; R^{101} is C_{1-6} alkyl group; R^a and R^b are independently the same or different hydrogen atom or methyl group; and R^{103} is optionally-substituted phenyl group.

[0210]

Step 14-1: Preparation process of compound (14-1)

Compound (14-1) is prepared by hydrolyzing compound (13-2) according to a similar process to a known process (e.g. Protective Groups in Organic Synthesis 3rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, by R. C. Larock, VCH publisher Inc., 1989).

In this case, compound (14-1) may be also used in the next reaction without any isolation.

For example, compound (13-2) is hydrolyzed according to the above process to neutralize the reaction solution and then the solvent is removed to give compound (14-1), and the resulting compound may be used in Step 14-2.

[0211]

Step 14-2: Preparation process of compound (14-2)

Compound (14-2) is prepared from compounds (14-1) and (1-6) according to the process of Step 1-4.

[0212]

Step 14-3: Preparation process of compound (14-3)

Compound (14-3) is prepared by hydrogenating benzyl group in compound (14-2) with a metal catalyst in an appropriate solvent to cleave the group.

Examples of the metal catalyst include palladium/carbon, Raney nickel, platinum oxide/carbon, and rhodium/carbon.

The amount of the metal catalyst to be used for

compound (14-2) is typically 0.1% by weight to 1000% by weight, preferably 1% by weight to 100% by weight.

Examples of the solvent include an alcohol such as methanol; an ether such as tetrahydrofuran; and an ester
5 such as ethyl acetate.

The hydrogen pressure is typically 1 atm to 100 atms, preferably 1 atm to 5 atms.

The reaction temperature is typically 0°C to 120°C, preferably 20°C to 80°C, but is not limited thereto. The
10 reaction time is typically 30 minutes to 72 hours, preferably 1 hour to 48 hours.

[0214] Also, when R¹⁰³ is phenyl group substituted with group(s) such as 4-methoxy group and 2,4-dimethoxy group, compound (14-3) is prepared by reacting compound (14-2)
15 with an acid.

[0215] Examples of the acid include TFA, formic acid, hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, methanesulfonic acid, and (±) 10-camphorsulfonic acid.

Examples of the solvent used include dichloromethane,
20 1,2-dichloroethane, 1,4-dioxane, THF, toluene, ethyl acetate, methanol, ethanol, 2-propanol, and a mixture thereof.


The reaction temperature is typically 0°C to 100°C, preferably 25°C to 50°C, but is not limited thereto. The
25 reaction time is typically 30 minutes to 12 hours,

preferably 1 hour to 9 hours.

[0216]

Preparation 15

One of the compounds of formula (1'), the compound of
5 formula (14-2) is prepared according to, for example, the
following process.



wherein W^1 , R^1 , R^2 , R^4 , n , ring Q^1 , and ring Q^2 are as
defined in the above [1]; R^{101} is C_{1-6} alkyl group; R^a and R^b
10 are independently the same or different hydrogen atom or
methyl group; X is halogen atom; A is boronic acid,
boronate, BF_3K , or BF_3Na ; and R^{103} is optionally-substituted
phenyl group.

[0217]

15 Step 15-1: Preparation process of compound (15-1)

Compound (15-1) is prepared by hydrolyzing compound
(2-1) according to a similar process to a known process
(e.g. Protective Groups in Organic Synthesis 3rd Edition

(John Wiley & Sons, Inc.), Comprehensive Organic Transformation, by R. C. Larock, VCH publisher Inc., 1989).

In this case, compound (15-1) may be also used in the next reaction without any isolation.

5 For example, compound (2-1) is hydrolyzed according to the above process to neutralize the reaction solution and then the solvent is removed to give compound (15-1), and the resulting compound may be used in Step 15-2.

[0218]

10 Step 15-2: Preparation process of compound (15-2)

Compound (15-2) is prepared from compounds (15-1) and (1-6) according to the process of Step 1-4.

[0219]

Step 15-3: Preparation process of compound (14-2)

15 Compound (14-2) is prepared by reacting compound (15-2) with compound (13-1) in an inert solvent in the presence of a palladium catalyst and a base.

[0220] Examples of the palladium catalyst include
 tetrakis(triphenylphosphine)palladium (0),
 20 bis(dibenzylideneacetone)palladium (0),
 tris(dibenzylideneacetone)dipalladium (0), bis(tri-*tert*-
 butylphosphine)palladium (0), [1,1'-
 bis(diphenylphosphino)ferrocene]palladium (II) dichloride.

25 Examples of the base include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate,

sodium hydroxide, and potassium hydroxide.


Examples of the inert solvent include 1,4-dioxane, THF, 1,2-dimethoxyethane, water, and a mixture thereof.

The reaction temperature is typically 50°C to 200°C, preferably 80°C to 150°C, but is not limited thereto. The reaction time is typically 1 hour to 48 hours, preferably 6 hours to 18 hours.

[0221]

Preparation 16

One of the compounds of formula (1'), the compound of formula (1-7) is prepared according to, for example, the following process.



wherein W^1 , W^3 , R^1 , R^2 , R^4 , R^5 , n , ring Q^1 , and ring Q^2 are as defined in the above [1]; R^{102} is protective group; and L

is a leaving group (such as iodine atom, bromine atom, chlorine atom, and substituted sulfonyloxy group (such as methanesulfonyloxy group and p-toluenesulfonyloxy group)).

[0222]

5 Step 16-1: Preparation process of compound (16-1)

Compound (16-1) is prepared by introducing a protective group into nitrogen atom in the 1-position of imidazole group in compound (1-3) in an inert solvent. Examples of the protective group include 2-
10 (trimethylsilyl)ethoxymethyl, benzyloxycarbonyl, *tert*-butoxycarbonyl, acetyl, and benzyl.

[0223] For example, when 2-(trimethylsilyl)ethoxymethyl group is introduced, compound (16-1) is prepared by reacting compound (1-3) with 2-(trimethylsilyl)ethoxymethyl
15 chloride in an inert solvent in the presence of a base.

[0224] Examples of the base include potassium carbonate, sodium carbonate, cesium carbonate, potassium *tert*-butoxide, sodium hydride, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, potassium
20 bis(trimethylsilyl)amide, and lithium diisoproylamide.

Examples of the inert solvent include DMF, THF, acetonitrile, and a mixture thereof.

The reaction temperature is typically 0°C to 150°C, preferably 0°C to 100°C, but is not limited thereto. The
25 reaction time is typically 10 minutes to 24 hours,

preferably 20 minutes to 6 hours.

[0225]

Step 16-2: Preparation process of compound (16-2)

Compound (16-2) is prepared from compound (16-1)
5 according to the process of Step 1-3.

[0226]

Step 16-3: Preparation process of compound (16-3)

Compound (16-3) is prepared from compounds (16-2) and
(1-2) according to the process of Step 1-4.

10 [0227]

Step 16-4: Preparation process of compound (16-4)

Compound (16-4) is prepared by cleaving the protective
group in nitrogen atom of imidazole group in compound (16-
3) in an inert solvent.

15 [0228] For example, when 2-(trimethylsilyl)ethoxymethyl
group is cleaved, compound (16-4) is prepared by reacting
compound (16-3) with an acid or a fluorinating reagent.

[0229] Examples of the acid include TFA, formic acid,
hydrochloric acid, sulfuric acid, p-toluenesulfonic acid,
20 methanesulfonic acid, and ($\pm$) 10-camphorsulfonic acid.

Examples of the fluorinating reagent include
tetrabutylammonium fluoride.

Examples of the solvent used include dichloromethane,
1,2-dichloroethane, 1,4-dioxane, THF, toluene, ethyl
25 acetate, methanol, ethanol, 2-propanol, and a mixture

thereof.

The reaction temperature is typically 0°C to 150°C, preferably 0°C to 50°C, but is not limited thereto. The reaction time is typically 5 minutes to 24 hours, preferably 1 hour to 9 hours.

[0230]

Step 16-5: Preparation process of compound (1-7)

Compound (1-7) is prepared from compounds (16-4) and (1-4) according to the process of Step 1-2.

[0231] The intermediates and desired compounds in the above preparations may be isolated and purified by a conventional purification method in organic synthetic chemistry such as neutralization, filtration, extraction, washing, drying, concentration, recrystallization, and each type of chromatography. The intermediates may be also used in the next reaction without any specific purification.

[0232] An optically-active product of the present compound can be prepared from an optically-active starting material or intermediate, or by the optical resolution of the racemate of a final product. The optical resolution method includes a physical separation method with optically-active column, and a chemical separation method such as a fractional crystallization method. A diastereomer of the present compound can be prepared by, for example, a fractional crystallization method.

[0233] The pharmaceutically acceptable salt of the compound of formula (1') can be prepared by, for example, mixing the compound of formula (1') with a pharmaceutically acceptable acid in a solvent such as water, methanol, ethanol, and acetone.

[0234] The present compound is used as, for example, an anti-tumor agent (anti-cancer agent). The applicable cancer type includes hematopoietic tumor and solid cancer, but is not limited thereto. Specific examples of the hematopoietic tumor include acute leukemia, chronic lymphatic leukemia, chronic myelocytic leukemia, polycythemia vera, malignant lymphoma, and myeloma, and specific examples of the solid cancer include brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small-cell lung cancer, non-small cell lung cancer, breast cancer, stomach cancer, gallbladder or bile duct cancer, liver cancer, pancreatic cancer, colon cancer, rectal cancer, ovarian cancer, chorioepithelioma, endometrial cancer, cervical cancer, urothelial cancer, renal cell cancer, prostate cancer, testicular tumor, Wilms' tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, and soft tissue sarcoma.

The anti-tumor agent is used for the prophylaxis and/or treatment of a cancer, and is expected to produce the reduction or disappearance of carcinoma or inhibit the

growth of carcinoma down to a certain level. The "prophylaxis" used herein means the administration of the active ingredient of the present invention to a healthy subject who does not develop a disease. For example, the prophylaxis is intended to prevent the development of a disease. The "treatment" used herein means the administration of the active ingredient of the present invention to a person diagnosed with the development of a disease by a doctor (*i.e.* a patient). For example, the treatment is intended to alleviate a disease or symptom thereof, inhibit the growth of carcinoma, or improve the condition of a patient to the previous condition before a disease is developed. Also, even if an anti-tumor agent is administered for the purpose of preventing the worsening of a disease or symptom thereof or the growth of carcinoma, the administration is referred to as "treatment" when the subject to be administered is a patient.

[0235] The present compound has any remarkable effects for inhibiting self-renewal ability of CSCs, and thus is expected to be useful as a novel anti-tumor agent for inhibiting the persistent proliferation, metastasis, and recurrence of malignant tumors derived from CSCs.

[0236] The present compound may be formulated into a suitable dosage form and administered orally or parenterally. Examples of the dosage form include a tablet,

a capsule, a powder, a granule, a solution, a suspension, an injection, a patch, and a poultice, but are not limited thereto. The preparation is formulated using pharmaceutically acceptable additive(s) according to a known method.

[0237] As appropriate, an additive such as an excipient, a disintegrant, a binder, a fluidizer, a lubricant, a coating agent, a solubilizer, a solubilizing agent, a thickening agent, a dispersant, a stabilizing agent, a sweetening agent, and a flavor may be used. Specific examples thereof include lactose, mannitol, crystalline cellulose, low substituted hydroxypropylcellulose, corn starch, partly pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylalcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, and talc.

[0238] The present compound may be used in combination with another drug(s) to enhance the therapeutic effect thereof and/or reduce side effects thereof. Specifically, the present compound can be used in combination with a drug such as a hormone therapeutic drug, a chemotherapeutic drug, an immunotherapeutic drug or a cell growth factor and a drug for inhibiting a receptor effect thereof. Hereinafter, a drug which can be used in combination with the present

compound is referred to as "combined medicine".

[0239] Examples of the combined medicine include an anticancer alkylating agent, an anticancer antimetabolite, an anticancer antibiotic, a plant-based anti-cancer agent, an anticancer platinum coordination compound, an anticancer camptothecin derivative, an anticancer tyrosine kinase inhibitor, a serine-threonine kinase, a phospholipid kinase, a monoclonal antibody, an interferon, a biological response modifier, a hormone preparation, an immune checkpoint inhibitor, an epigenetics-related molecule inhibitor, a post-translational protein modification inhibitor, and other anti-cancer agents.

[0240] The administration timing of the present compound and a combined medicine is not necessarily limited, and they may be administered simultaneously or administered with time-interval to a subject. In addition, the present compound and a combined medicine may be used in the form of a combination drug. The dosage of the combined medicine may be optionally determined based on the dosage in the clinical use. Also, the mixing ratio of the present compound and a combined medicine may be optionally determined depending on the subject to be administered, the administration route, the disease to be treated, the symptom, and a combination thereof. For example, when the subject is human, the combined medicine may be used in an

amount of 0.01 to 100 parts by weight relative to 1 part by weight of the present compound. In addition, a drug (a combined medicine) such as an antiemetic, a sleep inducing agent, and an anticonvulsant may be used in combination
5 with the present compound to inhibit side effects thereof.

[0241] The dosage can vary according to each compound and various conditions such as patient's disease, age, body weight, sex, symptom, and administration route. Typically, the present compound is administered to an adult (body
10 weight: 50 kg) at a dose of 0.1 to 1000 mg/day, preferably at a dose of 0.1 to 300 mg/day, which may be administered once a day or 2 or 3 times a day. In addition, the present compound may be administered once in several days to several weeks.

15

EXAMPLES

[0242] Hereinafter, the invention is illustrated in more detail with Reference Examples, Examples, and Test Examples, but the invention should not be limited thereto. The
20 compound names as shown in the following Reference Examples and Examples do not necessarily follow the IUPAC nomenclature system.

[0243] The following abbreviations may be used herein.

THF: tetrahydrofuran

25 TFA: trifluoroacetic acid

(Boc)₂O: di-*tert*-butyl dicarbonate

DBU: 1,8-diazabicyclo[5.4.0]-7-undecene

DMF: N,N-dimethylformamide

DME: 1,2-dimethoxyethane

5 DIEA: N,N-diisopropylethylamine

DMAP: N,N-dimethyl-4-aminopyridine

EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

EDCI·HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride

10 HOBt: 1-hydroxybenzotriazole

HOBt·H₂O: 1-hydroxybenzotriazole monohydrate

NBS: N-bromosuccinimide

TBSCl: *tert*-butyldimethylchlorosilane

Me: methyl

15 Et: ethyl

Ac: acetyl

Boc: *tert*-butoxycarbonyl

SEM: 2-(trimethylsilyl)ethoxymethyl

Rt: retention time

20 [0244] LC/MS analysis condition in the compound
identification is as follows.

LC/MS measurement:

Detection device: ACQUITY[®] SQ detector (Waters)

HPLC: ACQUITY UPLC[®] system

25 Column: Waters ACQUITY UPLC[®] BEH C18 (1.7 μm, 2.1 mm X 30

mm)

Solvent: A solution: 0.06% formic acid/H₂O, B solution:
0.06% formic acid/MeCN

Gradient condition: 0.0-1.3 min Linear gradient from B 2%
5 to 96%


Flow rate: 0.8 mL/min

UV: 220 nm and 254 nm

[0245]

Reference Example 1

10 4-Nitro-1-[3-(trifluoromethyl)benzyl]-1*H*-imidazole





A mixture of 4-nitro-1*H*-imidazole (35.8 g), 3-trifluoromethylbenzyl bromide (75.7 g), potassium iodide (0.131 g), potassium carbonate (48.1 g), and acetonitrile
15 (270 mL) was stirred at 80°C for 5 hours. The reaction mixture was cooled to room temperature, and then water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then concentrated *in*
20 *vacuo*. To the resulting solid was added diisopropyl ether (300 mL), and the mixture was stirred at room temperature for 1 hour. The resulting precipitate was collected on a filter, washed with diisopropyl ether, and dried at 50°C *in vacuo* to give the title compound (69.0 g).

LC-MS ($[M+H]^+/Rt$ (min)): 272.1/0.835

[0246]

Reference Examples 2-3


According to the process of Reference Example 1, the compounds of Reference Examples 2-3 were prepared from each corresponding starting compound.

Reference Examples	chemical structural formula	LC-MS : $[M+H]^+/Rt$ (min)
2		238.1/0.776
3		258.1/0.742

[0247]

Reference Example 4

1-[3-(Trifluoromethyl)benzyl]-1*H*-imidazole-4-amine hydrochloride



To the compound of Reference Example 1 (34.0 g) and rhodium-activated carbon (5%, 17.0 g) was added ethyl acetate (330 mL), and the mixture was stirred at room temperature under hydrogen atmosphere for 14 hours. The reaction mixture was filtered through Celite®, washed with ethyl acetate (50 mL x 4), and then to the filtrate was added hydrogen chloride (4 mol/L in ethyl acetate, 38.0 mL). The filtrate was concentrated *in vacuo*, and then to the



resulting crude product were added ethyl acetate (200 mL) and hexane (200 mL), and the mixture was stirred at room temperature for 10 minutes. The resulting precipitate was collected on a filter and washed with hexane/ethyl acetate (1/1, 20mL x 3), and then the resulting solid was dried at 40°C *in vacuo* to give the title compound (31.4 g).

LC-MS ($[M+H]^+$ /Rt (min)): 242.1/0.548

[0248]

Reference Examples 5-6


According to the process of Reference Example 4, the compounds of Reference Examples 5-6 were prepared from each corresponding starting compound.

Reference Examples	chemical structural formula	LC-MS : $[M+H]^+$ /Rt (min)
5		208.1/0.460
6		228.1/0.473

[0249]

Reference Example 7

Methyl 6-({1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}carbamoyl)nicotinate















To a suspension of the compound of Reference Example 4 (300 mg) in DMF (5 mL) were added 5-(methoxycarbonyl)picolinic acid (235 mg), EDCI·HCl (248 mg), HOBT (175 mg), and N,N-diisopropylethylamine (0.279 mL), and the mixture was stirred at room temperature for 2 hours. To the reaction mixture were added water and saturated aqueous sodium carbonate solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium carbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (281 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 404.9/0.901

[0250]


Reference Examples 8-19

According to the process of Reference Example 7, the compounds of Reference Examples 8-19 were prepared from each corresponding starting compound.

Reference Examples	chemical structural formula	LC-MS : [M+H] ⁺ /Rt (min)
8		404.9/0.780
9		443.1/0.960
10		415.2/0.992
11		503.1/1.017
12		411.2/0.897
13		395.2/0.863
14		395.2/0.888
15		415.1/0.915
16		431.1/0.942
17		415.1/0.849
18		489.0/0.991
19		401.1/0.967

Reference Example 20

6-Ethenyl-5-fluoro-N-{1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}nicotinamide



5 To a solution of the compound of Reference Example 9
(300 mg) in a mixture of 1,4-dioxane (5 mL)/water (0.5 mL)
were added vinylboronic acid pinacol ester (0.232 mL),
tetrakis(triphenylphosphine)palladium (78 mg), and
potassium carbonate (281 mg), and the mixture was stirred
10 under microwave irradiation at 120°C for 1 hour. The
reaction mixture was cooled to room temperature, and water
was added thereto, and then the mixture was extracted with
ethyl acetate. The organic layer was washed with brine,
dried over sodium sulfate, filtered, and then concentrated
15 *in vacuo*. The residue was purified by silica gel column
chromatography (hexane/ethyl acetate, ethyl
acetate/methanol) to give the title compound (122 mg).

LC-MS ([M+H]⁺/Rt (min)): 391.2/0.936

[0252]

20 Reference Examples 21-30

According to the process of Reference Example 20, the
compounds of Reference Examples 21-30 were prepared from
each corresponding starting compound.


Reference Examples	chemical structural formula	LC-MS : [M+H] ⁺ /Rt (min)
2 1		407.2/1.004
2 2		451.2/1.017
2 3		403.3/0.895
2 4		387.2/0.767
2 5		387.2/0.815
2 6		407.2/0.894
2 7		379.2/0.897
2 8		363.2/0.834
2 9		437.1/0.989
3 0		393.2/0.976

[0253]

Reference Example 31

6-Ethenyl-5-methyl-N-[1-(3,4,5-trifluorobenzyl)-1H-

imidazol-4-yl]nicotinamide




To a solution of the compound of Reference Example 29 (200 mg) in THF (4 mL) were added bis(tri-tert-butylphosphine)palladium (0) (23 mg) and methylzinc chloride (2 mol/L in THF, 0.69 mL), and the mixture was stirred at room temperature for 2 hours. To the reaction mixture were added saturated aqueous ammonium chloride solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium carbonate solution and brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by amino silica gel column chromatography (chloroform/methanol) to give the title compound (135 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 373.2/0.824

[0254]

Reference Example 32

6-(1,2-Dihydroxyethyl)-5-methoxy-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide



To a solution of the compound of Reference Example 23 (490 mg) in acetone (5 mL)/water (2.5 mL) were added N-methylmorpholine-N-oxide (285 mg) and osmium tetroxide (2.5 wt% in *tert*-butanol, 0.764 mL), and the mixture was stirred at room temperature for 24 hours. To the reaction mixture were then added saturated aqueous sodium thiosulfate solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by amino silica gel column chromatography (chloroform/methanol) to give the title compound (142 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 437.3/0.684

[0255]

Reference Examples 33-38


According to the process of Reference Example 32, the compounds of Reference Examples 33-38 were prepared from each corresponding starting compound.

Reference Examples	chemical structural formula	LC-MS : [M+H] ⁺ /Rt (min)
3 3		421. 2/0. 642
3 4		421. 2/0. 656
3 5		441. 2/0. 710
3 6		397. 2/0. 647
3 7		471. 2/0. 702
3 8		407. 2/0. 612

[0256]

Reference Example 39-1

6-(Chloromethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-
 5 imidazol-4-yl}nicotinamide



To a suspension of the compound of Example 12 (400 mg)


in THF were added lithium chloride (90 mg), N,N-diisopropylethylamine (0.366 mL) and then methanesulfonyl chloride (0.165 mL), and the mixture was stirred at room temperature for 4 hours. Lithium chloride (45 mg), N,N-diisopropylethylamine (0.183 mL), and methanesulfonyl chloride (0.083 mL) were added thereto, and then the mixture was additionally stirred at room temperature for 17 hours. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (269 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 395.2/0.835

[0257]

Reference Example 39-2

6-[(Di-*tert*-butoxycarbonyl)aminomethyl]-N-{1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}nicotinamide



To a solution of di-*tert*-butyl iminodicarbonate (586 mg) in DMF (3 mL) was added sodium hydride (118 mg), and the mixture was stirred at room temperature for 25 minutes. To the reaction mixture was added a solution of the


compound of Reference Example 39-1 obtained by the above process (213 mg) in DMF (6 mL), and the mixture was stirred at room temperature for 2 hours and then at 50°C for 4 hours. The mixture was cooled to room temperature, and to
5 the reaction mixture was added saturated aqueous ammonium chloride solution, and then the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column
10 chromatography (chloroform/methanol) to give the title compound (119 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 576.5/1.080

[0258]

Reference Example 40

15 Ethyl 6-(ethoxymethyl)-nicotinate



To ethanol (20 mL) was added sodium (237 mg) over 1 hour, and ethyl 6-(bromomethyl)-nicotinate (500 mg) was added thereto, and then the mixture was stirred at room
20 temperature overnight. The reaction mixture was concentrated *in vacuo* to remove the ethanol, and saturated aqueous sodium hydrogen carbonate solution was added thereto, and then the mixture was extracted with chloroform.


The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (159 mg).

5 LC-MS ($[M+H]^+/R_t$ (min)): 210.3/0.800

[0259]

Reference Example 41-1

Methyl 5-[(*tert*-butoxycarbonyl)amino]-6-chloro-nicotinate




10 To a solution of methyl 5-amino-6-chloro-nicotinate (325 mg) in THF (10 mL) were added di-*tert*-butyl dicarbonate (760 mg) and DMAP (11 mg), and the mixture was stirred at room temperature for 15.5 hours. Additional di-*tert*-butyl dicarbonate (38 mg) was added thereto, and the
15 mixture was stirred at 60°C for 45 minutes. The mixture was cooled to room temperature, and then the solvent was removed. To the residue were added methanol (5 mL) and potassium carbonate (481 mg), and the mixture was stirred at room temperature for 2.5 hours. Saturated aqueous
20 ammonium chloride solution was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The

residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (321 mg).
LC-MS ($[M+H]^+$ /Rt (min)): 287.1/0.985
[0260]

5 Reference Example 41-2

Methyl 5-[(*tert*-butoxycarbonyl)amino]-6-ethenyl-nicotinate




According to the process of Reference Example 20, the title compound was prepared from the compound of Reference
10 Example 41-1.

LC-MS ($[M+H]^+$ /Rt (min)): 279.5/0.885
[0261]

Reference Example 41-3

Methyl 5-[(*tert*-butoxycarbonyl)amino]-6-formyl-nicotinate



15 To a solution of the compound of Reference Example 41-2 (207 mg) in a mixture of acetone (8 mL)/water (4 mL) were added sodium periodate (659 mg) and osmium tetroxide (2.5 wt% in *tert*-butanol, 0.71 mL), and the mixture was stirred
20 at room temperature for 3 hours. To the reaction mixture were then added saturated aqueous sodium thiosulfate


solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (110 mg).

LC-MS ($[M+H]^+/R_t$ (min)): 281.2/1.037

[0262]

Reference Example 41-4

Methyl 5-[(*tert*-butoxycarbonyl)amino]-6-(hydroxymethyl)-nicotinate




To a solution of the compound of Reference Example 41-3 (110 mg) in methanol was added sodium borohydride (15 mg), and the mixture was stirred at room temperature for 1 hour. To the reaction mixture were then added saturated aqueous ammonium chloride solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo* to give the title compound (111 mg).

LC-MS ($[M+H]^+/R_t$ (min)): 282.8/0.761

[0263]

Reference Example 41-5

2-Oxo-1,4-dihydro-2H-pyrido[3,2-d][1,3]oxazine-7-carboxylic acid




To a solution of the compound of Reference Example 41-4 (111 mg) in THF (2 mL)/methanol (4 mL) was added 2 mol/L aqueous sodium hydroxide solution (0.39 mL), and the mixture was stirred at room temperature for 16 hours. To the reaction solution was added 2 mol/L hydrochloride (0.25 mL) to adjust pH to 7. The reaction mixture was concentrated *in vacuo* to give the title compound (76 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 195.1/0.325

[0264]

Reference Example 41-6

2-Oxo-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}-1,4-dihydro-2H-pyrido[3,2-d][1,3]oxazine-7-carboxamide




According to the process of Reference Example 7, the title compound was prepared from the compounds of Reference Examples 41-5 and 4.

LC-MS ($[M+H]^+$ /Rt (min)): 418.2/0.711

[0265]

Reference Example 42

2-Oxo-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]-1,4-dihydro-2*H*-pyrido[3,2-*d*][1,3]oxazine-7-carboxamide




5 According to the process of Reference Example 7, the title compound was prepared from the compounds of Reference Examples 41-5 and 6.

LC-MS ($[M+H]^+$ /Rt (min)): 404.2/0.670

[0266]

10 Reference Example 43-1

Methyl 6-chloro-5-(dibromomethyl)-nicotinate



To a suspension of methyl 6-chloro-5-methyl-nicotinate (467 mg) in carbon tetrachloride (25 mL) were added N-bromosuccinimide (1.34 g) and benzoyl peroxide (218 mg),
 15 and the mixture was stirred at 100°C for 7.5 hours. The mixture was cooled to room temperature, and to the reaction mixture were added saturated aqueous sodium thiosulfate solution and water, and then the mixture was extracted with
 20 chloroform. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then


concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (833 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 341.9/1.011

5 [0267]

Reference Example 43-2

Methyl 6-chloro-5-formyl-nicotinate




To a solution of the compound of Reference Example 43-1 (2.71 g) in acetonitrile (40 mL)/water (20 mL) was added silver nitrate (6.70 g), and the mixture was stirred at 100°C for 3 hours. The insoluble product was removed by filtration, and the solvent was removed. To the residue was added saturated aqueous sodium hydrogen carbonate solution to adjust pH to 8, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo* to give the title compound (0.84 g).

20 LC-MS ($[M+H]^+$ /Rt (min)): 200.0/0.671

[0268]

Reference Example 43-3

Methyl 6-chloro-5-(difluoromethyl)-nicotinate




To a solution of the compound of Reference Example 43-2 (0.84 g) in dichloromethane (20 mL) was added DAST (1.11 mL) with ice-cooling, and the mixture was stirred with ice-cooling for 30 minutes. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution to adjust pH to 8, and the mixture was extracted with chloroform. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (0.45 g).

LC-MS ($[M+H]^+$ /Rt (min)): 222.0/0.828

[0269]

Reference Example 43-4

Methyl 5-(difluoromethyl)-6-(hydroxymethyl)-nicotinate




According to the processes of Reference Examples 20, 41-3, and 41-4, the title compound was prepared from the compound of Reference Example 43-3.

LC-MS ($[M+H]^+$ /Rt (min)): 218.1/0.564

[0270]

Reference Example 44


Methyl 6-(hydroxymethyl)-5-(trifluoromethyl)-nicotinate



5 According to the processes of Reference Examples 20, 41-3, and 41-4, the title compound was prepared from methyl 6-chloro-5-(trifluoromethyl)-nicotinate.

LC-MS ($[M+H]^+$ /Rt (min)): 236.1/0.649

[0271]

10 Reference Example 45-1Methyl 5-(2-*tert*-butoxy-2-oxoethoxy)-picolinate


To a solution of methyl 5-hydroxy-picolinate (200 mg) in DMF (5 mL) were added potassium carbonate (361 mg) and *tert*-butyl bromoacetate, and the mixture was stirred at 15 70°C for 20 minutes. The mixture was cooled to room temperature, and to the reaction mixture was added water, and then the mixture was extracted with ethyl acetate. The organic layer was washed with brine twice, dried over 20 anhydrous sodium sulfate, filtered, and then concentrated *in vacuo* to give the title compound (320 mg).

LC-MS ($[M+H]^+/R_t$ (min)): 268.2/0.777

[0272]

Reference Example 45-2

{[6-(Methoxycarbonyl)pyridin-3-yl]oxy}acetic acid



5


To a solution of the compound of Reference Example 45-1 (320 mg) in dichloromethane (4 mL) was added TFA (2mL), and the mixture was stirred at room temperature for 2 hours. The solvent was removed to give the title compound (253mg).

10 LC-MS ($[M+H]^+/R_t$ (min)): 212.1/0.394

[0273]

Reference Example 45-3

Methyl 5-(2-oxo-2-{[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]amino}ethoxy)-picolinate



15


According to the process of Reference Example 7, the title compound was prepared from the compounds of Reference Example 45-2 and 6.

LC-MS ($[M+H]^+/R_t$ (min)): 421.2/0.731

20 [0274]

Reference Example 46-1

4-([*Tert*-butyl(dimethyl)silyl]oxy)methyl)-5-methyl-1,3-thiazole-2-carboxylic acid



To a solution of (2-bromo-5-methyl-1,3-thiazol-4-yl)methanol (151 mg) in DMF (3 mL) was added imidazole (59 mg) and TBSCl (131 mg), and the mixture was stirred at room temperature for 1 hour. To the reaction mixture were then added saturated aqueous ammonium chloride solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous ammonium chloride solution and brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 2-bromo-4-([*tert*-butyl(dimethyl)silyl]oxy)methyl)-5-methyl-1,3-thiazole.

To a solution of the resulting 2-bromo-4-([*tert*-butyl(dimethyl)silyl]oxy)methyl)-5-methyl-1,3-thiazole in THF (4 mL) was added *n*-butyllithium (0.91 mL) at -78°C , and the mixture was stirred at this temperature for 1 hour. An excess amount of powdered dry ice was then added thereto, and the mixture was stirred at this temperature for 45 minutes and then at room temperature for 40 minutes. To


the reaction mixture was added saturated aqueous ammonium chloride solution, and then the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo* to give the title compound (127 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 288.1/1.058

[0275]

Reference Example 46-2

4-({[*Tert*-butyl(dimethyl)silyl]oxy)methyl)-5-methyl-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]-1,3-thiazole-2-carboxamide




According to the process of Reference Example 7, the title compound was prepared from the compounds of Reference Examples 46-1 and 6.

LC-MS ($[M+H]^+$ /Rt (min)): 497.1/1.314

[0276]

Reference Example 47

5-({[*Tert*-butyl(dimethyl)silyl]oxy)methyl)-4-methyl-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]-1,3-thiazole-2-carboxamide




According to the processes of Reference Examples 46-1 and 7, the title compound was prepared from the corresponding starting compound.

5 LC-MS ($[M+H]^+$ /Rt (min)): 497.1/1.333
[0277]

Reference Example 48

6-Formyl-N-{1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}nicotinamide



10


To a suspension of the compound of Example 12 (200 mg) in dichloromethane (10 mL) was added manganese dioxide (2 g), and the mixture was stirred at room temperature for 19 hours. The reaction mixture was filtered through Celite[®],
15 and the filter cake was washed with ethyl acetate and methanol. The filtrate was concentrated *in vacuo*, and the residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (55 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 375.2/0.793

20 [0278]

Reference Example 49-1

Methyl 1-(3,4,5-trifluorobenzyl)-1*H*-imidazole-4-carboxylate




To a solution of methyl 1*H*-imidazole-4-carboxylate (14.0 g) in acetonitrile (200 mL) were added potassium carbonate (19.9 g) and potassium iodide (0.092 g), and 3,4,5-trifluorobenzyl bromide (14.6 mL) was added dropwise thereto at room temperature, and then the mixture was stirred at 70°C for 6 hours. The mixture was cooled to room temperature, and to the reaction mixture was added water, and then the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and then concentrated *in vacuo*. The resulting crude product was washed with hexane/ethyl acetate (1/2, 60 mL) to give the title compound (14.0 g).

LC-MS ($[M+H]^+$ /Rt (min)): 271.4/0.725

[0279]

Reference Example 49-2

1-(3,4,5-Trifluorobenzyl)-1*H*-imidazole-4-carboxylic acid



To a solution of the compound of Reference Example 49-1 (4.75 g) in methanol/THF (50 mL/50 mL) was added 2 mol/L


aqueous sodium hydroxide solution (13.2 mL), and the mixture was stirred at 50°C for 5 hours. The reaction mixture was concentrated *in vacuo*, and the residue was dissolved in water, and then aqueous hydrochloric acid solution was added thereto to adjust pH to 5. The resulting precipitate was collected on a filter, washed with water and hexane, and then dried at 50°C *in vacuo* to give the title compound (4.52 g).

LC-MS ($[M+H]^+$ /Rt (min)): 257.1/0.513

[0280]

Reference Example 50

6-([*Tert*-butyl(dimethyl)silyl]oxy)methyl)pyridine-3-amine




To a solution of (5-aminopyridin-2-yl)methanol (135 mg) in THF (15 mL) were added triethylamine (0.30 mL) and TBSCl (328 mg), and the mixture was stirred at room temperature for 6 hours. The solvent was removed *in vacuo*, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (99 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 239.2/0.726

[0281]

Reference Example 51

2-([*Tert*-butyl(dimethyl)silyl]oxy)methyl)quinoline-6-amine



According to the process of Reference Example 50, the title compound was prepared from (6-aminoquinolin-2-yl)methanol.

5 LC-MS ($[M+H]^+/R_t$ (min)): 289.9/0.836

[0282]

Reference Examples 52-53


According to the process of Reference Example 7, the compounds of Reference Examples 52-53 were prepared from
10 the compound of Reference Example 49 and each corresponding starting compound.

Reference Examples	chemical structural formula	LC-MS : $[M+H]^+/R_t$ (min)
5 2		527.3/1.289
5 3		411.2/0.915

[0283]

Reference Example 54

15 Methyl 6-(3-hydroxyprop-1-en-2-yl)nicotinate



To a solution of methyl 6-methylnicotinate (420 mg) in

water (2 mL) were added triethylamine (0.065 mL) and paraformaldehyde (42 mg), and the mixture was stirred under microwave irradiation at 150°C for 3 hours. To the reaction mixture was added water, and the mixture was
5 extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (24 mg).


10 LC-MS ($[M+H]^+$ /Rt (min)): 194.1/0.532

^1H -NMR (400 MHz, CDCl_3): δ 9.15–9.13 (1H, m), 8.29 (1H, dd, $J = 8.4, 2.0$ Hz), 7.70 (1H, d, $J = 8.4$ Hz), 5.94 (1H, s), 5.65 (1H, s), 4.61 (2H, s), 3.97 (3H, s).

[0284]

15 Reference Example 55

Methyl 6-[(1*E*)-3-hydroxyprop-1-en-1-yl]nicotinate



To a solution of (2*E*)-3-[5-(methoxycarbonyl)pyridin-2-yl]prop-2-enoic acid (50 mg) in DME (1 mL) were added N-methylmorpholine (0.056 mL) and isobutyl chloroformate
20 (0.035 mL), and the mixture was stirred at 0°C for 1 hour. The precipitate was removed by filtration, and the filtrate was concentrated to give a crude product of mixed anhydrate.

To a suspension of sodium borohydride (23.3 mg) in


THF/water (2 mL/0.5 mL) was added a solution of the resulting mixed anhydrate in THF at 0°C. The reaction solution was stirred at room temperature for 3 hours. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (19 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 194.3/0.741

[0285]

Reference Example 56-1

Methyl 6-(oxiran-2-yl)-nicotinate




To a solution of ethyl 6-ethenyl-nicotinate (210 mg) in *tert*-butylalcohol/water (6 mL/3 mL) was added NBS (232 mg), and the mixture was stirred at 40°C for 2 hours. The reaction was quenched with aqueous sodium hydroxide solution in an ice bath, and the reaction solution was neutralized with hydrochloric acid, and then the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then concentrated *in vacuo*.

The residue was dissolved in THF (10 mL), and sodium hydride (78 mg) was added thereto in an ice bath, and the mixture was stirred at room temperature for 1 hour. To the reaction mixture was added brine, and the mixture was
 5 extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (125.3 mg).

10 LC-MS ($[M+H]^+$ /Rt (min)): 194.1/0.654
 [0286]

Reference Example 56-2

Ethyl 6-(2-hydroxyethyl)-nicotinate



15 To a solution of the compound of Reference Example 56-1 (125 mg) in ethanol (10 mL) were added 5% palladium/carbon (138 mg) and ammonium formate (204 mg), and the mixture was stirred at 50°C for 3 hours. The palladium was filtered through Celite®, and the filtrate
 20 was concentrated *in vacuo*. The residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give the title compound (87.3 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 196.1/0.467


$^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 9.12 (1H, d, $J = 2.4$ Hz), 8.23

(1H, dd, $J = 8.0, 2.4$ Hz), 7.26 (1H, d, $J = 8.0$ Hz), 4.41 (2H, q, $J = 7.6$ Hz), 4.06-4.03 (2H, m), 3.11-3.07 (2H, m), 1.41 (3H, t, $J = 7.6$ Hz).

[0287]

5 Reference Example 57

Methyl 5-(hydroxymethyl)pyrazine-2-carboxylate




According to the processes of Reference Examples 20, 41-3, and 41-4, the title compound was prepared from methyl
10 5-chloropyrazine-2-carboxylate.

LC-MS ($[M+H]^+/R_t$ (min)): 169.0/0.334

[0288]

Reference Example 58

6-({Methyl[(2-nitrophenyl)sulfonyl]amino}methyl)-N-{1-[3-(
15 (trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}nicotinamide



To a solution of the compound of Example 12 (101 mg) in chloroform (4 mL) were added N-methyl-2-nitrobenzenesulfonamide (79 mg), diethyl azodicarboxylate (2.2 mol/L toluene solution, 159 μ L), and
20 triphenylphosphine (92 mg), and the mixture was stirred at room temperature for 20 hours. N-methyl-2-


nitrobenzenesulfonamide (80 mg), diethyl azodicarboxylate (2.2 mol/L toluene solution, 159 μ L), and triphenylphosphine (93 mg) were additionally added thereto, and the mixture was stirred at 60°C for 6 hours. N-methyl-
 5 2-nitrobenzenesulfonamide (157 mg), diethyl azodicarboxylate (2.2 mol/L toluene solution, 318 μ L), and triphenylphosphine (194 mg) were additionally added thereto, and the mixture was stirred at 60°C for 2 hours. The reaction solution was concentrated *in vacuo*, and the
 10 residue was purified by silica gel chromatography (hexane/ethyl acetate) to give the title compound (174 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 575.3/0.944

[0289]

Reference Example 59-1

15 Methyl 5-ethenyl-6-hydroxy-nicotinate




According to the process of Reference Example 20, the title compound was prepared from methyl 5-bromo-6-hydroxynicotinate.

20 LC-MS ($[M+H]^+$ /Rt (min)): 180.0/0.541

[0290]

Reference Example 59-2

Methyl 6-chloro-5-ethenyl-nicotinate




To a suspension of the compound of Reference Example 59-1 (1.37 g) in phosphorous oxychloride (14.3 mL) was stirred at 90°C for 1 hour. The reaction mixture was cooled to room temperature and concentrated *in vacuo*. The residue was diluted with ethyl acetate, neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo* to give the title compound (1.45 g).

LC-MS ($[M+H]^+$ /Rt (min)): 198.0/0.870

[0291]

Reference Example 59-3

Methyl 6-chloro-5-formyl-nicotinate




According to the process of Reference Example 41-3, the title compound was prepared from the compound of Reference Example 59-2.

LC-MS ($[M+H]^+$ /Rt (min)): 200.0/0.671

[0292]

Reference Example 60-1

Isopropyl 5-bromo-6-chloro-nicotinate




A suspension of 5-bromo-6-hydroxy-nicotinic acid (10
5 g) in thionyl chloride (17 mL)/DMF (0.36 mL) was stirred at
80°C for 2 hours. The reaction mixture was cooled to room
temperature and concentrated *in vacuo*. To the residue was
then added 2-propanol (25 mL), and the mixture was stirred
at 100°C for 40 minutes. The reaction mixture was cooled
10 to room temperature and concentrated *in vacuo*. To the
residue were then added saturated aqueous sodium carbonate
solution and water, and the mixture was extracted with
ethyl acetate. The organic layer was washed with brine,
dried over sodium sulfate, filtered, and then concentrated
15 *in vacuo* to give the title compound (12.4 g).

LC-MS ($[M+H]^+$ /Rt (min)): 278.0/1.102

[0293]

Reference Example 60-2

Isopropyl 6-chloro-5-formyl-nicotinate



20

To a solution of the compound of Reference Example 60-

1 (2.0 g) in THF (30 mL) was cooled to -20°C, and isopropylmagnesium chloride lithium chloride complex (1.3 mol/L in THF, 7.2 mL) was added thereto, and then the reaction mixture was stirred at -20°C for 35 minutes.

5 Isopropylmagnesium chloride lithium chloride complex (1.3 mol/L in THF, 0.55 mL) was added thereto, and the mixture was additionally stirred at -20°C for 25 minutes. DMF (1.11 mL) was added thereto, and the reaction mixture was stirred at room temperature for 1 hour 10 minutes.


10 Saturated aqueous ammonium chloride solution and water were added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo* to give the title compound (1.64 g).

15 LC-MS ($[M+H]^+/R_t$ (min)): 228.1/0.897

[0294]

Reference Example 60-3

Isopropyl 6-chloro-5-(difluoromethyl)-nicotinate




20 According to the process of Reference Example 43-3, the title compound was prepared from the compound of Reference Example 60-2.

LC-MS ($[M+H]^+/R_t$ (min)): 250.1/1.014

[0295]

Reference Example 60-4

Isopropyl 6-bromo-5-(difluoromethyl)-nicotinate




5 To a solution of the compound of Reference Example 60-
 3 (500 mg) in acetonitrile (10 mL) was added
 bromotrimethylsilane (0.52 mL), and the mixture was stirred
 at 100°C for 4 hours. The reaction mixture was cooled to
 room temperature, and then concentrated *in vacuo*. The
 10 residue was purified by silica gel column chromatography
 (hexane/ethyl acetate) to give the title compound (585 mg).
 LC-MS ($[M+H]^+$ /Rt (min)): 294.0/1.035

[0296]

Reference Example 60-5

15 Isopropyl 5-(difluoromethyl)-6-{[(4-methoxybenzyl)oxy]methyl}-nicotinate



To a solution of the compound of Reference Example 60-
 4 (100 mg) in 1,4-dioxane (3 mL)/water (0.3 mL) were added
 20 [1,1'-bis(diphenylphosphino)ferrocene]palladium (II)
 dichloride dichloromethane adduct (28 mg), potassium (4-

methoxy)benzyloxymethyltrifluoroborate (114 mg), and cesium carbonate (222 mg), and then the mixture was stirred at 120°C for 9.5 hours. The reaction mixture was cooled to room temperature and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (70 mg).


LC-MS ($[M+H]^+/R_t$ (min)): 366.5/1.129

$^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 9.20 (1H, s), 8.54 (1H, s), 7.27 (2H, d, $J = 8.7$ Hz), 7.16 (1H, t, $J = 54.8$ Hz), 6.89 (2H, d, $J = 8.7$ Hz), 5.30 (1H, sep, $J = 5.9$ Hz), 4.83 (2H, s), 4.52 (2H, s), 3.81 (3H, s), 1.40 (6H, d, $J = 5.9$ Hz).

[0297]

Reference Example 60-6

Isopropyl 5-(difluoromethyl)-6-(hydroxymethyl)-nicotinate



To a solution of the compound of Reference Example 60-5 (44 mg) in dichloromethane (1.5 mL) was added TFA (1.5 mL), and the mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated *in vacuo*, and the residue was neutralized with saturated aqueous sodium hydrogen carbonate solution, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in*


vacuo. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (16 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 246.1/0.756

5 [0298]

Reference Example 61

Tert-butyl 5-bromo-6-chloro-nicotinate



A suspension of 5-bromo-6-hydroxy-nicotinic acid (10 g) in thionyl chloride (17 mL)/DMF (0.36 mL) was stirred at 80°C for 2 hours. The reaction mixture was cooled to room temperature and concentrated *in vacuo*. To the residue were added toluene (50 mL), *N,N*-diisopropylethylamine (16 mL), and *tert*-butanol (22 mL), and then the mixture was stirred at room temperature for 3 hours and then at 80°C for 1 hour. DMAP (0.28 g) was added thereto, and the mixture was additionally stirred at 80°C for 2 hours. The reaction mixture was cooled to room temperature, and saturated aqueous sodium carbonate solution and water were added thereto, and then the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium carbonate solution, saturated aqueous potassium hydrogen sulfate solution, saturated aqueous


sodium hydrogen carbonate solution, and then brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (5.85 g).

LC-MS ($[M+H]^+/R_t$ (min)): 292.0/1.188

[0299]

Reference Example 62

Isopropyl 5-(difluoromethyl)-6-iodo-nicotinate




According to the process of Reference Example 60-4, the title compound was prepared from the compound of Reference Example 60-3 and iodotrimethylsilane.

LC-MS ($[M+H]^+/R_t$ (min)): 342.0/1.054

[0300]

Reference Example 63

Methyl 5-(difluoromethyl)-6-iodo-nicotinate




According to the process of Reference Example 60-4, the title compound was prepared from the compound of Reference Example 43-3 and iodotrimethylsilane.

LC-MS ($[M+H]^+/Rt$ (min)): 314.0/0.875

[0301]

Reference Example 64-1

4-Nitro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1*H*-imidazole




A suspension of sodium hydride (3.04 g) in DMF (15 mL) was cooled with an ice, and a solution of 4-nitroimidazole (5.66 g) in DMF (40 mL) was added thereto, and then the mixture was stirred with ice-cooling for 45 minutes. 2-(Trimethylsilyl)ethoxymethyl chloride (9.65 mL) was added thereto, and the mixture was stirred at room temperature for 2 hours. Methanol, an ice, and brine were added thereto, and the mixture was extracted with hexane/ethyl acetate (1/1). The organic layer was dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (8.62 g).

LC-MS ($[M+H]^+/Rt$ (min)): 244.1/0.927

[0302]

20 Reference Example 64-2

1-{[2-(Trimethylsilyl)ethoxy]methyl}-1*H*-imidazole-4-amine



A suspension of the compound of Reference Example 64-1


(7.84 g) and rhodium/carbon (3.92 g) in ethyl acetate (200 mL) was stirred under hydrogen atmosphere at room temperature for 10 hours. The reaction mixture was filtered through Celite®, and to the filtrate was added
 5 hydrogen chloride (4 mol/L in 1,4-dioxane, 8 mL), and then the mixture was concentrated *in vacuo* to give the title compound (6.22 g).

LC-MS ($[M+H]^+/R_t$ (min)): 214.2/0.665

[0303]

10 Reference Example 64-3

5-(Difluoromethyl)-6-{[(4-methoxybenzyl)oxy]methyl}-N-(1-
 {[2-(trimethylsilyl)ethoxy]methyl}-1*H*-imidazol-4-
 yl)nicotinamide




15 According to the process of Example 49, the title compound was prepared from the compounds of Reference Examples 64-2 and 60-5.

LC-MS ($[M+H]^+/R_t$ (min)): 519.4/1.105

[0304]

20 Reference Example 64-4

5-(Difluoromethyl)-6-(hydroxymethyl)-N-(1*H*-imidazol-4-
 yl)nicotinamide




According to the process of Example 50, the title compound was prepared from the compound of Reference Example 64-3.

LC-MS ($[M+H]^+$ /Rt (min)): 269.1/0.322

5 [0305]

Reference Example 65-1

N-{1-[3-(Trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}prop-2-enamide



10 To a solution of the compound of Reference Example 4 (1 g) and DIEA (1.4 mL) in THF (25 mL) was added acryloyl chloride (0.32 mL) slowly. The reaction mixture was stirred at room temperature for 1.5 hours, and water was added thereto, and then the mixture was extracted with
15 chloroform. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (0.13 g).


20 LC-MS ($[M+H]^+$ /Rt (min)): 296.2/0.718

$^1\text{H-NMR}$ (400 MHz, DMSO-d_6): δ 10.56 (1H, s), 7.69-7.66 (3H, m), 7.62-7.57 (2H, m), 7.33 (1H, s), 6.44 (1H, dd, $J = 17.1$, 10.4 Hz), 6.15 (1H, dd, $J = 17.1$, 2.4 Hz), 5.63 (1H, dd, $J = 10.4$, 2.4 Hz), 5.27 (2H, s).

[0306]

Reference Example 65-2

Methyl 5-[(1*E*)-3-oxo-3-({1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}amino)prop-1-en-1-yl]picolinate



5

To a solution of the compound of Reference Example 65-1 (60 mg) in DMF (2 mL) were added methyl 5-bromopicolinate (53 mg), dichlorobis(tri-*O*-tolylphosphine)palladium (II) (16 mg), and triethylamine (0.042 mL), and the mixture was stirred at 90°C for 3.5 hours and then at 130°C for 2 hours. The mixture was cooled to room temperature, and water and a small amount of methanol were added thereto, and then the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The resulting residue was purified by amino silica gel column chromatography (ethyl acetate/methanol) to give the title compound (42 mg).

10

15

LC-MS ($[M+H]^+$ /Rt (min)): 431.2/0.790


20

$^1\text{H-NMR}$ (400 MHz, DMSO- d_6): δ 10.73 (1H, s), 8.87 (1H, s), 8.14-8.08 (2H, m), 7.71-7.56 (6H, m), 7.41 (1H, s), 7.07 (1H, d, $J = 15.8$ Hz), 5.29 (2H, s), 3.88 (3H, s).

[0307]

Reference Example 66

Ethyl (2E)-3-[6-(hydroxymethyl)pyridin-3-yl]prop-2-enoate




To a solution of 2-ethoxycarbonyl vinylboronic acid
5 pinacol ester (361 mg) in 1,4-dioxane (15 mL)/water (1.5
mL) were added 5-bromo-2-hydroxymethylpyridine (300 mg),
bis(tri-*t*-butylphosphine)palladium (0) (122 mg), and
potassium carbonate (662 mg), and the mixture was stirred
under microwave irradiation at 130°C for 1.5 hours. The
10 reaction mixture was cooled to room temperature, and water
was added thereto, and then the mixture was extracted with
ethyl acetate. The organic layer was washed with brine,
dried over anhydrous sodium sulfate, filtered, and then
concentrated *in vacuo*. The resulting residue was purified
15 by silica gel column chromatography (hexane/ethyl acetate)
to give the title compound (204 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 208.1/0.476

[0308]

Reference Example 67

20 Ethyl (2E)-3-[5-chloro-6-(hydroxymethyl)pyridin-3-yl]prop-
2-enoate




According to the process of Reference Example 66, the title compound was prepared from the corresponding starting compound.

5 LC-MS ($[M+H]^+/R_t$ (min)): 242.1/0.719
[0309]

Reference Example 68-1

6-Chloro-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]pyridazine-3-carboxamide



10


According to the process of Reference Example 7, the title compound was prepared from the compound of Reference Example 6 and the commercially available starting compound.

LC-MS ($[M+H]^+/R_t$ (min)): 368.2/0.820

15 [0310]

Reference Example 68-2

6-Ethenyl-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]pyridazine-3-carboxamide




According to the process of Reference Example 20, the title compound was prepared from the compound of Reference Example 68-1.

5 LC-MS ($[M+H]^+/R_t$ (min)): 360.2/0.809

[0311]

Example 1

5-(Hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}picolinamide



10

To a solution of Reference Example 7 (100 mg) in THF (2 mL)/methanol (1 mL) was added lithium borohydride (3 mol/L in THF, 0.08 mL), and the mixture was stirred at room temperature for 3 hours. To the reaction mixture were added saturated aqueous ammonium chloride solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. To the resulting solid were added ethyl acetate (2 mL) and hexane (2 mL), and the mixture was placed in an ultrasound bath, and then the resulting solid was collected

15

20

LC-MS ([M+H]⁺/Rt (min)): 377.2/0733

Examples 2-3

10

[0313]

6-[Hydroxy(²H₂)methyl]-N-{1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}nicotinamide



To a suspension of lithium aluminum deuteride (21 mg) in THF (3 mL) was added the compound of Reference Example 8

(100 mg) with ice-cooling, and the mixture was stirred at this temperature for 30 minutes and then at room temperature for 2 hours. Lithium aluminum deuteride (11 mg) was added thereto, and the mixture was additionally stirred at room temperature for 1 hour. Water (0.040 mL), 10% aqueous sodium hydroxide solution (0.060 mL), and then water (0.12 mL) were added thereto, and the mixture was stirred at room temperature for 20 minutes. The insoluble product was removed by filtration, and the residue was washed with water, ethyl acetate/methanol (1/1), ethyl acetate, and then methanol. The filtrate was concentrated *in vacuo*, and to the residue were added methanol and water, and then the mixture was placed in an ultrasound bath. The resulting precipitate was collected on a filter, washed with water, and then dried at 50°C *in vacuo* to give the title compound (53 mg).


LC-MS ($[M+H]^+$ /Rt (min)): 379.2/0.673

$^1\text{H-NMR}$ (400 MHz, DMSO- d_6): δ 11.00 (1H, s), 9.01 (1H, d, J = 1.8 Hz), 8.30 (1H, d, J = 8.2, 1.8 Hz), 7.73-7.68 (3H, m), 7.64-7.61 (2H, m), 7.54 (1H, d, J = 8.2 Hz), 7.47 (1H, d, J = 1.2 Hz), 5.48 (1H, s), 5.31 (2H, s).

[0314]

Example 5

6-(2-Hydroxypropan-2-yl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide



To a solution of the compound of Reference Example 8 (70 mg) in THF (5 mL) was added methylmagnesium bromide (0.97 mol/L in THF, 0.89 mL), and the mixture was stirred at room temperature for 20 hours. Methylmagnesium bromide (0.97 mol/L in THF, 0.45 mL) was added thereto, and the mixture was additionally stirred for 5.5 hours. To the reaction mixture were added saturated aqueous ammonium chloride solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (10 mg).


LC-MS ($[M+H]^+/R_t$ (min)): 405.2/0.742

$^1\text{H-NMR}$ (400 MHz, DMSO-d_6): δ 10.97 (1H, s), 8.99 (1H, s), 8.27 (1H, d, $J = 8.2$ Hz), 7.77–7.61 (6H, m), 7.47 (1H, s), 5.31–5.30 (3H, m), 1.44 (6H, s).

[0315]

Example 6

6-(1-Hydroxyethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide



According to the process of Example 5, the title compound was prepared from the compound of Reference Example 48.

5 LC-MS ($[M+H]^+$ /Rt (min)): 391.2/0.717

^1H -NMR (400 MHz, DMSO- d_6) : δ 10.98 (1H, s), 9.00 (1H, d, J = 1.8 Hz), 8.29 (1H, dd, J = 8.3, 1.8 Hz), 7.73-7.72 (2H, m), 7.70-7.68 (1H, m), 7.64-7.61 (2H, m), 7.57 (1H, d, J = 8.3 Hz), 7.47 (1H, d, J = 1.2 Hz), 5.46 (1H, d, J = 4.9 Hz),
 10 5.30 (2H, s), 4.75 (1H, qd, J = 6.7, 4.9 Hz), 1.36 (3H, d, J = 6.7 Hz).

[0316]

Examples 7-9


15 According to the process of Reference Example 7, the compounds of Examples 7-9 were prepared from the corresponding compounds of each Reference Example.

Examples	chemical structural formula	LC-MS : [M+H] ⁺ /Rt (min)
7		383.2/0.729
8		369.1/0.690
9		391.2/0.773

[0317]

Example 10

6-(Hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide



To a solution of methyl 6-(hydroxymethyl)-nicotinate (0.924 g) in THF (22 mL) was added 5 mol/L aqueous potassium hydroxide solution (2.2 ml). The mixture was stirred at room temperature overnight, concentrated *in vacuo* to remove the solvent, and then dried *in vacuo*. To a solution of the resulting solid in DMF (25 mL) were added the compound of Reference Example 6 (1.61 g), HATU (2.52 g), and diisopropylethylamine (2.38 mL), and the mixture was stirred at room temperature for 1 hour. To the reaction

mixture were then added saturated aqueous sodium hydrogen carbonate solution and water, and the resulting precipitate was collected on a filter. The resulting filter cake was washed with water/acetonitrile and then ethyl acetate, and
5 dried *in vacuo* to give the title compound (1.375 g).







LC-MS ($[M+H]^+$ /Rt (min)): 363.1/0.66

^1H -NMR (400 MHz, DMSO- d_6) : δ 11.00 (1H, s), 9.01 (1H, d, J = 1.8 Hz), 8.30 (1H, dd, J = 7.9, 1.8 Hz), 7.69 (1H, d, J = 1.2 Hz), 7.54 (1H, d, J = 7.9 Hz), 7.48 (1H, d, J = 1.2 Hz),
10 7.38-7.30 (2H, m), 5.52 (1H, t, J = 6.1 Hz), 5.18 (2H, s), 4.60 (2H, d, J = 6.1 Hz).

[0318]

Examples 11-21

According to the process of Example 10, the compounds
15 of Examples 11-21 were prepared from the corresponding compounds of each Reference Example.


Examples	chemical structural formula	instrumental analysis data
1 1		LC-MS : [M+H] ⁺ /Rt (min): 343.2/0.611
1 2		¹ H-NMR (400 MHz, DMSO-d ₆): 10.99 (1H, s), 9.01 (1H, d, J = 1.8 Hz), 8.30 (1H, dd, J = 8.5, 1.8 Hz), 7.73-7.72 (2H, m), 7.70-7.68 (1H, m), 7.64-7.59 (2H, m), 7.54 (1H, d, J = 8.5 Hz), 7.47 (1H, d, J = 1.2 Hz), 5.51 (1H, t, J = 6.1 Hz), 5.31 (2H, s), 4.60 (2H, d, J = 6.1 Hz). LC-MS : [M+H] ⁺ /Rt (min): 377.3/0.672
1 3		LC-MS : [M+H] ⁺ /Rt (min): 377.2/0.637
1 4		LC-MS : [M+H] ⁺ /Rt (min): 403.3/0.712
1 5		¹ H-NMR (400 MHz, DMSO-d ₆): 9.88 (1H, s), 9.06 (1H, s), 8.22-8.18 (1H, m), 7.72 (1H, d, J = 8.4 Hz), 7.61 (1H, d, J = 8.0 Hz), 7.54-7.44 (4H, m), 7.39 (1H, d, J = 8.0 Hz), 5.92 (1H, s), 5.64 (1H, s), 5.61 (2H, s), 4.61 (2H, s). LC-MS : [M+H] ⁺ /Rt (min): 403.3/0.745
1 6		¹ H-NMR (400 MHz, DMSO-d ₆): 11.03 (1H, s), 9.03 (1H, d, J = 1.8 Hz), 8.31 (1H, dd, J = 7.9, 2.4 Hz), 7.69 (1H, d, J = 1.8 Hz), 7.51-7.48 (2H, m), 7.38-7.31 (2H, m), 5.18 (2H, s), 4.58 (2H, s), 3.56 (2H, q, J = 6.7 Hz), 1.19 (3H, t, J = 6.7 Hz). LC-MS : [M+H] ⁺ /Rt (min): 391.3/0.82

Examples	chemical structural formula	instrumental analysis data
17		¹ H-NMR (400 MHz, DMSO-d ₆): 11.27 (1H, s), 9.17 (1H, d, J = 1.8 Hz), 8.54 (1H, d, J = 1.8 Hz), 7.75–7.73 (2H, m), 7.70–7.68 (1H, m), 7.64–7.61 (2H, m), 7.49 (1H, d, J = 1.2 Hz), 7.42 (1H, t, J = 54.3 Hz), 5.61 (1H, t, J = 5.8 Hz), 5.31 (2H, s), 4.75 (2H, d, J = 5.8 Hz). LC-MS : [M+H] ⁺ /Rt (min): 427.2/0.787
18		¹ H-NMR (400 MHz, DMSO-d ₆): 11.27 (1H, s), 9.17 (1H, s), 8.54 (1H, s), 7.71 (1H, s), 7.51 (1H, s), 7.42 (1H, t, J = 54.8 Hz), 7.37–7.33 (2H, m), 5.61 (1H, t, J = 5.8 Hz), 5.19 (2H, s), 4.75 (2H, d, J = 5.8 Hz). LC-MS : [M+H] ⁺ /Rt (min): 413.2/0.751
19		LC-MS : [M+H] ⁺ /Rt (min): 445.2/0.852
20		LC-MS : [M+H] ⁺ /Rt (min): 378.2/0.713
21		¹ H-NMR (400 MHz, DMSO-d ₆): 10.97 (1H, s), 7.73–7.68 (3H, m), 7.64–7.57 (2H, m), 7.45 (1H, s), 6.81 (1H, s), 5.73 (1H, t, J = 5.8 Hz), 5.30 (2H, s), 4.60 (2H, d, J = 5.8 Hz). LC-MS : [M+H] ⁺ /Rt (min): 367.2/0.735

[0319]

Example 22

N-[6-(Hydroxymethyl)pyridin-3-yl]-1-(3,4,5-trifluorobenzyl)-1H-imidazole-4-carboxamide



To a solution of the compound of Reference Example 49-
 2 (138 mg) and the compound of Reference Example 50 (141
 mg) in DMF (15 mL) were added EDCI·HCl (124 mg), HOBT (87
 5 mg), and N,N-diisopropylethylamine (0.188 mL), and the
 mixture was stirred at 80°C for 6 hours. To the reaction
 mixture were then added water and aqueous sodium hydroxide
 solution, and the mixture was extracted with chloroform.
 The organic layer was washed with brine, dried over
 10 magnesium sulfate, filtered, and then concentrated *in vacuo*.
 The resulting residue was dissolved in methanol (5 mL), and
 2 mol/L hydrochloric acid/methanol (0.81 mL) was added
 thereto, and then the mixture was stirred at 40°C for 5
 hours. To the reaction mixture was added water and then
 15 aqueous sodium hydroxide solution, and the mixture was
 extracted with chloroform. The organic layer was washed
 with brine, dried over magnesium sulfate, filtered, and
 then concentrated *in vacuo*. The residue was purified by
 silica gel column chromatography (chloroform/methanol) to
 20 give the title compound (86.4 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 363.2/0.640


^1H -NMR (400 MHz, DMSO- d_6): δ 10.06 (1H, s), 8.84 (1H, s),
 8.19-8.14 (1H, m), 7.97-7.95 (2H, m), 7.42-7.34 (3H, m),

5.31-5.26 (1H, m), 5.24 (2H, s), 4.48 (2H, d, J = 4.8 Hz).

[0320]

Example 23

N-[2-(hydroxymethyl)quinolin-6-yl]-1-(3,4,5-trifluorobenzyl)-1H-imidazole-4-carboxamide



According to the process of Example 22, the title compound was prepared from the compounds of Reference Examples 49-2 and 51.


LC-MS ([M+H]⁺/Rt (min)):413.3/0.673

¹H-NMR (400 MHz, DMSO-d₆):δ 10.13 (1H, s), 8.49 (1H, d, J = 2.0 Hz), 8.24 (1H, d, J = 9.2 Hz), 8.04 (1H, dd, J = 9.2, 2.0 Hz), 8.00 (1H, s), 7.98 (1H, s), 7.85 (1H, d, J = 8.8 Hz), 7.57 (1H, d, J = 8.8 Hz), 7.44-7.38 (2H, m), 5.50-5.46 (1H, m), 5.25 (2H, s), 4.60 (2H, d, J = 5.6 Hz).

[0321]

Example 24

6-(Aminomethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide ditrifluoroacetate



According to the process of Reference Example 45-2,


the title compound was prepared from the compound of Reference Example 39-2.

LC-MS ($[M+H]^+/R_t$ (min)): 376.2/0.597

[0322]

5 Example 25

6-[(Acetylamino)methyl]-N-{1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}nicotinamide



To a solution of the compound of Example 24 (30 mg) in THF (1 mL) were added triethylamine (0.111 mL) and anhydrous acetic acid (0.038 mL), and the mixture was stirred at room temperature for 1.5 hours. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (28 mg).

LC-MS ($[M+H]^+/R_t$ (min)): 418.3/0.669


$^1\text{H-NMR}$ (400 MHz, DMSO-d_6): δ 11.02 (1H, s), 9.01 (1H, d, J = 1.8 Hz), 8.48 (1H, t, J = 6.1 Hz), 8.26 (1H, dd, J = 8.3, 1.8 Hz), 7.73-7.68 (3H, m), 7.64-7.59 (2H, m), 7.46 (1H, s), 7.35 (1H, d, J = 8.3 Hz), 5.30 (2H, s), 4.37 (2H, d, J =

6.1 Hz), 1.90 (3H, s).

[0323]

Example 26

6-[(Methylamino)methyl]-N-{1-[3-(trifluoromethyl)benzyl]-
5 1*H*-imidazol-4-yl}nicotinamide



To a solution of the compound of Reference Example 58 (155 mg) in DMF (1 mL) were added potassium carbonate (59 mg) and thiophenol (30 μ L), and the mixture was stirred at
10 room temperature for 3 hours. To the reaction mixture was added diethyl ether, and the organic layer was extracted with 0.1 mol/L hydrochloric acid. To the resulting aqueous layer was added saturated aqueous sodium hydrogen carbonate solution to adjust pH to 9, and the mixture was extracted
15 with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*, and then the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (93 mg).

20 LC-MS ($[M+2H]^{2+}/R_t$ (min)): 195.7/0.628

[0324]

Examples 27-29

According to the process of Reference Example 32, the


compounds of Examples 27-29 were prepared from the corresponding compounds of each Reference Example.

Examples	chemical structural formula	LC-MS : [M+H] ⁺ /Rt (min)
27		425.3/0.697
28		441.2/0.791
29		485.2/0.742

[0325]

5 Example 30

5-Fluoro-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide



To a solution of the compound of Example 27 (51 mg) in THF (2 mL)/water (1 mL) was added sodium periodate (77 mg), and the mixture was stirred at room temperature for 1 hour. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate,










filtered, and then concentrated *in vacuo*. To a solution of the resulting residue in methanol (1 mL) was added sodium borohydride (4 mg), and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was
5 added saturated aqueous ammonium chloride solution, and the mixture was stirred at room temperature for 5 minutes, and then concentrated *in vacuo*. To the residue was added water, and the mixture was placed in an ultrasound bath, and then the precipitate was collected on a filter. The resulting
10 filter cake was washed with water and methanol, and then dried at 50°C *in vacuo* to give the title compound (37 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 395.3/0.739

[0326]


Examples 31-39

15 According to the process of Example 30, the compounds of Examples 31-39 were prepared from the compounds of Examples 28-29 and the corresponding compounds of each Reference Example.

Examples	chemical structural formula	instrumental analysis data
3 1		¹ H-NMR (400 MHz, DMSO-d ₆): 11.17 (1H, s), 9.01 (1H, d, J = 1.8 Hz), 8.39 (1H, d, J = 1.8 Hz), 7.76–7.68 (3H, m), 7.64–7.59 (2H, m), 7.48 (1H, s), 5.34 (1H, t, J = 6.1 Hz), 5.31 (2H, s), 4.67 (2H, d, J = 6.1 Hz). LC-MS : [M+H] ⁺ /Rt (min): 411.2/0.791
3 2		LC-MS : [M+H] ⁺ /Rt (min): 455.2/0.806
3 3		LC-MS : [M+H] ⁺ /Rt (min): 407.3/0.711
3 4		LC-MS : [M+H] ⁺ /Rt (min): 391.2/0.646
3 5		LC-MS : [M+H] ⁺ /Rt (min): 391.2/0.669
3 6		LC-MS : [M+H] ⁺ /Rt (min): 411.2/0.743
3 7		LC-MS : [M+H] ⁺ /Rt (min): 367.2/0.681
3 8		LC-MS : [M+H] ⁺ /Rt (min): 441.1/0.769
3 9		¹ H-NMR (400 MHz, DMSO-d ₆): 10.97 (1H, s), 8.87 (1H, d, J = 1.8 Hz), 8.10 (1H, d, J = 1.8 Hz), 7.69 (1H, d, J = 1.2 Hz), 7.48 (1H, d, J = 1.2 Hz), 7.38–7.31 (2H, m), 5.18 (2H, s), 5.11 (1H, t, J = 5.5 Hz), 4.60 (2H, d, J = 5.5 Hz), 2.35 (3H, s). LC-MS : [M+H] ⁺ /Rt (min): 377.2/0.631

Example 40

2-(Hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1*H*-imidazol-4-yl}-1,3-thiazole-5-carboxamide



5 To a solution of the compound of Reference Example 27 (211 mg) in acetone (5 mL)/water (2.5 mL) were added osmium tetroxide (2.5 wt% in *tert*-butanol, 0.525 mL) and sodium periodate (358 mg), and the mixture was stirred at room temperature for 4 hours. To the reaction mixture were

10 added saturated aqueous sodium thiosulfate solution and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was roughly purified by silica gel column chromatography (chloroform/methanol). To the resulting

15 compound were added methanol (2 mL) and sodium borohydride (3 mg), and then the mixture was stirred at room temperature for 18.5 hours. To the reaction mixture was added saturated aqueous ammonium chloride solution and

20 water, and then the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified by silica gel column chromatography (chloroform/methanol) to give the title

compound (8 mg).


LC-MS ($[M+H]^+/\text{Rt (min)}$): 383.2/0.705

$^1\text{H-NMR}$ (400 MHz, DMSO-d_6): δ 9.77 (1H, s), 8.31 (1H, s),
7.72-7.71 (2H, m), 7.70-7.67 (1H, m), 7.62-7.60 (2H, m),
5 7.40 (1H, d, $J = 1.8$ Hz), 6.19 (1H, t, $J = 5.8$ Hz), 5.30
(2H, s), 4.77 (2H, d, $J = 5.8$ Hz).

[0328]

Example 41

5-Chloro-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-
10 imidazol-4-yl]nicotinamide




According to the process of Example 40, the title compound was prepared from the compound of Reference Example 30.

15 LC-MS ($[M+H]^+/\text{Rt (min)}$): 397.2/0.750

[0329]

Example 42

6-(Hydroxymethyl)-5-methyl-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide



20

According to the process of Reference Example 31, the

title compound was prepared from the compound of Example 32.

LC-MS ($[M+H]^+$ /Rt (min)): 391.3/0.671


^1H -NMR (400 MHz, DMSO- d_6): δ 10.96 (1H, s), 8.86 (1H, d, J = 1.8 Hz), 8.10 (1H, d, J = 1.8 Hz), 7.73-7.68 (3H, m), 7.64-7.59 (2H, m), 7.46 (1H, d, J = 1.8 Hz), 5.31 (2H, s), 5.12 (1H, t, J = 5.8 Hz), 4.60 (2H, d, J = 5.8 Hz), 2.35 (3H, s).

[0330]

Example 43

5-Ethenyl-6-(hydroxymethyl)-N-{1-[3-

(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide




According to the process of Reference Example 20, the title compound was prepared from the compound of Example 32.

LC-MS ($[M+H]^+$ /Rt (min)): 403.3/0.744

[0331]

Example 44

5-Ethyl-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide



To a suspension of platinum oxide (30 mg) in ethyl acetate (2 mL)/methanol (1 mL) was added the compound of


Example 43 (27 mg), and the mixture was stirred under hydrogen atmosphere at room temperature for 4 hours. The reaction mixture was filtered through Celite® and washed with ethyl acetate. The filtrate was concentrated *in vacuo*,
5 and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, ethyl acetate/methanol) to give the title compound (16 mg).

LC-MS ($[M+H]^+/R_t$ (min)): 405.3/0.708

[0332]

10 Example 45

5-Amino-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide



To a suspension of the compound of Reference Example
15 41-6 (13 mg) in THF (0.5 mL)/methanol (0.5 mL) was added 2 mol/L aqueous sodium hydroxide solution (0.031 mL), and the mixture was stirred at 60°C for 3 hours and then at 90°C for 6.5 hours. The reaction mixture was cooled to room temperature, and water was added thereto, and then the
20 mixture was stirred at room temperature for 5 minutes. The resulting solid was collected on a filter, washed with water, and dried at 50°C *in vacuo* to give the title compound (7 mg).


LC-MS ($[M+H]^+/R_t$ (min)): 392.2/0.647

^1H -NMR (400 MHz, DMSO- d_6) : δ 10.79 (1H, s), 8.29 (1H, d, J = 1.8 Hz), 7.72-7.68 (3H, m), 7.64-7.581 (2H, m), 7.43 (1H, d, J = 1.2 Hz), 7.42 (1H, d, J = 1.8 Hz), 5.36 (2H, s),
 5 5.30 (2H, s), 5.18 (1H, t, J = 5.5 Hz), 4.52 (2H, d, J = 5.5 Hz)

[0333]

Example 46

5-Amino-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-
 10 imidazol-4-yl]nicotinamide




According to the process of Example 45, the title compound was prepared from the compound of Reference Example 42.

15 LC-MS ($[M+H]^+/R_t$ (min)): 378.2/0.603

[0334]

Example 47

4-(Hydroxymethyl)-5-methyl-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]-1,3-thiazole-2-carboxamide



20

To the compound of Reference Example 46-2 (219 mg) was


added hydrogen chloride (2 mol/L in methanol, 2 mL), and the mixture was added at room temperature for 1 hour. To the reaction mixture were added saturated aqueous sodium hydrogen carbonate solution, water, and ethyl acetate, and then the mixture was stirred at room temperature for 10 minutes. The resulting precipitate was collected on a filter, washed with water and hexane, and then dried at 50°C *in vacuo* to give the title compound (84 mg).

LC-MS ($[M+H]^+$ /Rt (min)): 383.2/0.769

[0335]

Example 48

5-(Hydroxymethyl)-4-methyl-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]-1,3-thiazole-2-carboxamide




According to the process of Example 47, the title compound was prepared from the compound of Reference Example 47.

LC-MS ($[M+H]^+$ /Rt (min)): 383.2/0.743

[0336]

Example 49

5-(Difluoromethyl)-6-{[(4-methoxybenzyl)oxy]methyl}-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]nicotinamide




To a solution of the compound of Reference Example 60-5 (2.49 g) in methanol (25 mL) was added 2 mol/L aqueous sodium hydroxide solution (6.8 mL), and the mixture was stirred at room temperature for 1 hour. To the reaction solution was added 4 mol/L hydrochloric acid (2.1 mL) to adjust pH to 8. The reaction mixture was concentrated *in vacuo*, and to a suspension of the resulting residue in THF (30 mL) were added DIEA (1.43 mL) and diphenyl chlorophosphate (1.70 mL), and then the mixture was stirred for 2 hours. DIEA (1.43 mL) and diphenyl chlorophosphate (1.70 mL) were added thereto, and the mixture was additionally stirred for 1 hour. DIEA (2.86 mL) and the compound of Reference Example 6 (1.97 g) were added thereto, and the mixture was stirred at room temperature for 20 hours. 2 mol/L aqueous sodium hydroxide solution (10 mL) was added thereto, and the mixture was stirred at room temperature for 2 hours. 2 mol/L aqueous sodium hydroxide solution (5 mL) was added thereto, and the mixture was additionally stirred for 1.5 hours. Methanol (15 mL) was added thereto, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated *in vacuo*, and the residue was diluted with

water and then extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium carbonate solution and brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified
5 by silica gel column chromatography (hexane/ethyl acetate, ethyl acetate/methanol) to give the title compound (1.88 g).
LC-MS ($[M+H]^+$ /Rt (min)): 534.3/1.021
[0337]

Example 50

10 5-(Difluoromethyl)-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]nicotinamide



To a solution of the compound of Example 49 (1.88 g) in chloroform (10 mL) was added TFA (2 mL), and the mixture
15 was stirred at room temperature for 2 hours. To the reaction solution was added TFA (3 mL), and the mixture was additionally stirred for 3 hours. The reaction mixture was concentrated *in vacuo*, and to the residue were added water and saturated aqueous sodium carbonate solution, and then
20 the mixture was extracted with chloroform. The organic layer was washed with saturated aqueous sodium carbonate solution and brine, dried over sodium sulfate, filtered, and then concentrated *in vacuo*. The residue was purified

by silica gel column chromatography (chloroform/methanol) to give the title compound (0.53 g).

¹H-NMR (400 MHz, DMSO-d₆): δ 11.27 (1H, s), 9.17 (1H, s), 8.54 (1H, s), 7.71 (1H, s), 7.51 (1H, s), 7.42 (1H, t, J = 54.8 Hz), 7.37-7.33 (2H, m), 5.61 (1H, t, J = 5.8 Hz), 5.19 (2H, s), 4.75 (2H, d, J = 5.8 Hz).

LC-MS ([M+H]⁺/Rt (min)): 413.2/0.751

[0338]

Examples 51-52


According to the process of Example 49, the compounds of Examples 51-52 were prepared from the compound of Reference Example 4 and each corresponding starting compound.

Examples	chemical structural formula	LC-MS : [M+H] ⁺ /Rt (min)
51		403.3/0.678
52		437.2/0.782

[0339]

Example 53

(2E)-3-[6-(2-Hydroxypropan-2-yl)pyridin-3-yl]-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}prop-2-enamide



To a solution of the compound of Reference Example 65-2 (30 mg) in THF (2 mL) was added methylmagnesium bromide (0.97 mol/L in THF, 0.36 mL), and the mixture was stirred at room temperature for 1.5 hours. Methylmagnesium bromide (0.97 mol/L in THF, 0.36 mL) was added thereto, and the mixture was additionally stirred at room temperature for 16 hours. To the reaction mixture was added saturated aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated *in vacuo*. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (13 mg).



LC-MS ($[M+H]^+$ /Rt (min)): 431.3/0.722

$^1\text{H-NMR}$ (400 MHz, DMSO- d_6): δ 10.62 (1H, s), 8.64 (1H, s), 7.92 (1H, dd, $J = 8.2, 2.1$ Hz), 7.70-7.57 (6H, m), 7.50 (1H, d, $J = 15.9$ Hz), 7.38 (1H, s), 6.92 (1H, d, $J = 15.9$ Hz), 5.29 (2H, s), 5.25 (1H, s), 1.43 (6H, s).

[0340]

Examples 54-55


According to the process of Reference Example 1, the compounds of Examples 54-55 were prepared from the compound of Reference Example 64-4 and each corresponding starting compound.











Examples	chemical structural formula	LC-MS : [M+H] ⁺ /R _t (min)
5 4		395.2/0.698
5 5		393.2/0.732



















[0341]

Examples 56-84

According to the process of Reference Example 1, the compounds of Examples 56-84 were prepared from the compound of Reference Example 64-4 and each corresponding starting compound.




Exam ples	Q ¹ -W ¹ -	LC-MS: [M+H] ⁺ /R t (min)	Exam ples	Q ¹ -W ¹ -	LC-MS: [M+H] ⁺ /R t (min)
56		359.2/0.672	71		427.2/0.852
57		445.3/0.833	72		379.3/0.870
58		437.2/0.785	73		443.3/0.841
59		373.3/0.764	74		445.3/0.847
60		445.3/0.840	75		427.2/0.866

61		411.2/0. 810	76		455.2/0. 819
62		455.2/0. 837	77		419.3/0. 715
63		373.3/0. 745	78		411.2/0. 802
64		389.3/0. 697	79		395.2/0. 739
65		457.3/0. 849	80		473.1/0. 875
66		411.2/0. 796	81		360.2/0. 416
67		455.2/0. 815	82		417.2/0. 788
68		365.2/0. 776	83		441.3/0. 828
69		451.3/0. 906	84		409.3/0. 817
70		441.3/0. 874			

[0342]

Example 85

6-(Hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1*H*-imidazol-4-yl]pyridazine-3-carboxamide



According to the process of Example 40, the title

compound was prepared from the compound of Reference Example 68-2.

LC-MS ($[M+H]^+$ /Rt (min)): 364.2/0.706

[0343]

5 Test Example 1: Inhibition of sphere-forming ability of cancer cells

 The reliable methods established for measuring the self-renewal ability of cells which is one of the CSC's properties include a method for measuring the sphere-
10 forming ability of cancer cells in non-adherent condition in the absence of serum (Cancer Res 65, 5506-5511 (2005)). HCT-116 cells were available from the American Type Culture Collection (ATCC). HCT-116 cells were cultured at 37°C and 5% CO₂ using the McCoy's 5a medium containing 10% fetal
15 bovine serum (FBS) and 1% penicillin/streptomycin. HCT-116 cells were seeded in a 384 Well Black Clear Bottom Ultra-Low Attachment Microplate (Corning Cat. No.3827) in an amount of 350-800 cells/well using the DMEM/F12 medium containing 2% B27 supplement (GIBCO), 20 ng/mL epidermal
20 growth factor (EGF) (peprotech), 10 ng/mL basic fibroblast growth factor (bFGF) (peprotech), 5 µg/mL insulin (Sigma), and 1% penicillin/streptomycin. The test compounds were added into each well to adjust the final concentration of DMSO to 0.1%, and the cells were cultured for 4 days. The
25 number of viable cells in each well was then measured with

CellTiter-Glo[®] Luminescent Cell Viability Assay (Promega) to calculate the concentration of each test compound for 50% inhibition of cell proliferation (Sphere IC₅₀ value; $\mu\text{mol/L}$).

- 5 [0344] The experiment of Test Example 1 was performed for the compounds of each Example. The concentrations of each test compound for 50% inhibition of cell proliferation (Sphere IC₅₀ value; $\mu\text{mol/L}$) are shown in the following Table.

Examples	IC ₅₀ ($\mu\text{mol/L}$)	Examples	IC ₅₀ ($\mu\text{mol/L}$)
1	0.030	25	4.483
2	0.629	26	0.824
3	<0.01	27	0.695
4	<0.01	28	0.847
5	8.400	29	0.633
6	3.650	30	0.069
7	0.024	31	<0.01
8	0.077	32	<0.01
9	5.035	33	9.795
10	0.007	34	7.394
11	0.056	35	3.763
12	<0.01	36	0.074
13	0.675	37	0.238
14	6.039	38	0.061
15	0.710	39	<0.01
16	0.892	40	0.122
17	<0.01	41	0.051
18	<0.01	42	<0.01
19	0.070	43	5.597
20	0.053	44	0.758
21	0.653	45	0.029
22	<0.01	46	0.010

23	0.079	47	0.669
24	0.061	48	0.095
Examples	IC ₅₀ (μmol/L)	Examples	IC ₅₀ (μmol/L)
51	0.07	54	0.148
52	0.05	55	0.075
53	7.20		
Examples	IC ₅₀ (μmol/L)	Examples	IC ₅₀ (μmol/L)
56	0.430	69	0.070
57	<0.010	70	<0.010
58	0.070	71	<0.010
59	0.090	72	0.810
60	0.030	73	0.080
61	<0.010	74	0.380
62	<0.010	75	<0.010
63	0.690	76	0.050
64	0.090	78	0.050
65	0.630	79	0.080
66	0.070	82	0.720
67	0.040	83	0.700
68	0.280	85	0.020

[0345]

Test Example 2: Test for inhibiting sphere-forming ability of cancer cells (in the presence of BSA)

HCT-116 cells were available from the American Type Culture Collection (ATCC). HCT-116 cells were cultured at 37°C and 5% CO₂ using the McCoy's 5a medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. HCT-116 cells were seeded in a 384 Well Black Clear Bottom Ultra-Low Attachment Microplate (Corning Cat. No.3827) in an amount of 350-800 cells/well using the DMEM/F12 medium containing 2% B27 supplement (GIBCO), 20 ng/mL epidermal growth factor (EGF) (peprotech), 10 ng/mL basic fibroblast

growth factor (bFGF) (peprotech), 5 µg/mL insulin (Sigma), 5% bovine serum albumin (BSA), and 1% penicillin/streptomycin. The test compounds were added into each well to adjust the final concentration of DMSO to 0.1%, and the cells were cultured for 4 days. The number of viable cells in each well was then measured with CellTiter-Glo[®] Luminescent Cell Viability Assay (Promega) to calculate the concentration of each test compound for 50% inhibition of cell proliferation (Sphere IC₅₀ value; µmol/L).

[0346] The experiment of Test Example 2 was performed for the compounds of each Example. The concentrations of each test compound for 50% inhibition of cell proliferation (Sphere IC₅₀ value; µmol/L) are shown in the following Table.

Examples	IC ₅₀ (µmol/L)	Examples	IC ₅₀ (µmol/L)
1	0.350	27	6.230
2	0.605	28	4.585
3	0.051	29	3.501
4	0.061	30	0.563
6	6.970	31	<0.01
7	0.520	32	0.068
8	0.578	35	6.106
10	0.007	36	0.481
12	0.060	37	0.451
13	0.735	38	0.081
15	5.766	39	<0.01
16	1.446	40	0.629
17	0.057	41	0.059

18	0.053	42	0.060
19	0.403	43	6.511
20	0.313	44	5.112
21	0.767	45	0.059
22	<0.01	46	0.057
23	0.084	47	5.455
24	0.696	48	0.571
25	4.968		
Examples	IC ₅₀ (μmol/L)	Examples	IC ₅₀ (μmol/L)
51	0.63	54	0.603
52	0.41	55	0.619
53	>10		
Examples	IC ₅₀ (μmol/L)	Examples	IC ₅₀ (μmol/L)
56	0.540	69	0.330
57	0.050	70	0.060
58	0.080	71	0.060
59	0.100	72	0.670
60	0.060	73	0.080
61	0.030	74	0.670
62	0.050	75	0.050
63	0.600	76	0.060
64	0.290	78	0.060
65	0.660	79	0.060
66	0.060	82	0.470
67	0.070	83	0.580
68	0.540	85	0.030

[0347]

Test Example 3. Pharmacokinetic assay in mouse

A 7-week-old mouse (BALB/cAnNCr1Cr1j, female, CHARLES RIVER LABORATORIES JAPAN, INC.) receives single oral administration of each compound suspended in 0.5% methylcellulose solution in a dose of 10 mg/kg or 100 mg/kg. Blood is collected from the mouse 0.5, 1, 2, 4, 8 and 24 hours after the administration, and plasma from the blood

is collected by centrifugation. The area under the plasma concentration-time curve (AUC) is calculated on the basis of the concentration changes to calculate the bioavailability of each compound according to the following formula:

$$\text{Bioavailability (\%)} = \frac{\text{AUC after oral administration}}{\text{AUC after intravenous administration}} \times 100$$

Plasma is deproteinized by adding methanol at the final concentration of 80%, centrifuging the methanol solution, and filtrating the contrifuged solution, and then the present compound in the deproteinized plasma is detected and quantified with an LC-MS/MS (API4000, AB SCIEX). When the present compound is quantified, a calibration curve is prepared based on the mouse plasma added with a given amount of the compound. Bezafibrate is used as internal standard.

[0348]

Test Example 4. Anti-tumor effect to HCT-116 tumor-bearing mouse

The present compound can be used to evaluate the anti-tumor effect thereof. A 4 to 7-week-old nude mouse (BALB/cAnNCrj-nu/nu, female, CHARLES RIVER LABORATORIES JAPAN, INC.) received intradermal transplantation of HCT-116 cells (ATCC) in an amount of 3×10^6 cells/mouse around the ventral portion. The engraftment of HCT-116 cells was

observed 5 to 14 days after the transplantation, and then each compound suspended in a solvent such as 0.5% methylcellulose solution was orally administrated to the mouse in a dose of 1 to 100 mg/kg one to twice daily. The tumor volume was measured over time after the administration to evaluate the effect for reducing the tumor volume by the administration of each compound. The tumor volume can be calculated from the minor axis and the major axis of the tumor measured with a digital caliper (Mitutoyo) according to the following formula:

$$\text{Tumor volume [mm}^3\text{]} = 0.5 \times \text{minor axis [mm]} \times (\text{major axis [mm]})^2$$

The tumor volume in control administration group treated with only a solvent such as 0.5% methylcellulose solution was compared with that of the present compound administration group, and T/C value was calculated according the following formula to evaluate the anti-tumor effect of the present compound.

$$\text{T/C(\%)} = \frac{(\text{the tumor volume at the end of administration in the present compound administration group} - \text{the tumor volume at the start of administration in the present compound administration group})}{(\text{the tumor volume at the end of administration in the control administration group} - \text{the tumor volume at the start of administration in the control administration group})} \times 100$$

The T/C values (%) of the present compound on each dosage and administration period in the HCT-116 tumor-bearing mouse are shown below.


Examples	dosage (mg/kg)	administration period (day)	T/C (%)
12	100	16	49
17	30	17	74
17	100	17	75
18	30	17	63
18	100	17	54
39	30	17	79
39	100	17	65
45	30	17	90
45	100	17	81
46	30	17	91
46	100	17	91

5 INDUSTRIAL APPLICABILITY

[0349] The present compound has a potent inhibitory effect on sphere-forming ability of cancer cells, and is useful as an orally-available anti-tumor agent.

CLAIMS

1. A compound of formula (1'):



5 or a pharmaceutically acceptable salt thereof, wherein ring Q^1 is optionally-substituted C_{6-10} aryl group, optionally-substituted C_{3-10} cycloalkyl group, or optionally-substituted 5- to 10-membered heteroaryl group;

10 R^1 and R^2 are independently hydrogen atom, halogen atom, or C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

W^1 is optionally-substituted C_{1-4} alkylene group;

15 W^2-Q^2 is $-NR^{3a}C(O)-Q^2$, $-NR^{3a}C(O)O-Q^2$, $-NR^{3a}C(O)OCH_2-Q^2$, $-NR^{3a}C(O)NR^{3b}-Q^2$, $-NR^{3a}C(O)NR^{3b}CH_2-Q^2$, $-NR^{3a}C(O)CH_2O-Q^2$, $-NR^{3a}C(O)CH_2-Q^2$, $-NR^{3a}C(O)CH_2CH_2-Q^2$, $-C(O)NR^{3a}-Q^2$, $-C(O)NR^{3a}CH_2-Q^2$, $-C(O)NR^{3a}CH_2CH_2-Q^2$, or $-NR^{3a}C(O)-CR^{3c}=CR^{3d}-Q^2$ wherein R^{3a} and R^{3b} are independently hydrogen atom or C_{1-6} alkyl group; and R^{3c} and R^{3d} are independently hydrogen atom, fluorine atom, or C_{1-6} alkyl group;

20

ring Q^2 is 5- to 10-membered heteroaryl group;

W^3 is optionally-substituted C_{1-4} alkylene group, optionally-substituted C_{3-4} alkenylene group, or optionally-substituted C_{3-4} alkynylene group;

n is 1, 2, 3, 4, or 5;

5 R^4 is, independently when two or more exist, hydrogen atom, halogen atom, optionally-substituted C_{1-6} alkyl group, optionally-substituted C_{1-6} alkoxy group, optionally-substituted C_{3-10} cycloalkyl group, optionally-substituted C_{2-6} alkenyl group, optionally-substituted C_{2-6} alkynyl group, 10 cyano group, optionally-substituted C_{1-6} alkyl-carbonyl group, optionally-substituted C_{1-6} alkylsulfonyl group, optionally-substituted C_{1-6} alkoxy-carbonyl group, optionally-substituted C_{1-6} alkyl-carbonylamino group, optionally-substituted C_{1-6} alkylsulfonylamino group, 15 optionally-substituted C_{1-6} alkoxy-carbonylamino group, optionally-substituted C_{1-6} alkyl-carbonyloxy group, optionally-substituted amino group, optionally-substituted aminocarbonyl group, optionally-substituted aminosulfonyl group, optionally-substituted 5- or 6-membered cyclic amino 20 group, optionally-substituted 5- or 6-membered cyclic aminocarbonyl group, nitro group, or carboxyl group;

when R^4 and W^3 are attached to the adjacent carbon atoms on ring Q^2 , they may be combined with the carbon atoms to form 5- to 8-membered cycloalkane ring; and

25 R^5 is

(1) hydroxy group,


(2) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy,

5 C₁₋₆ alkoxy, and C₆₋₁₀ aryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

10 (3) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups, or

(4) C₁₋₆ alkyl-carbonylamino group wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 halogen atoms.

15 2. A compound of formula (1):



or a pharmaceutically acceptable salt thereof, wherein ring Q¹ is optionally-substituted C₆₋₁₀ aryl group, optionally-substituted C₃₋₁₀ cycloalkyl group, or optionally-substituted 5- to 10-membered heteroaryl group;

R¹ and R² are independently hydrogen atom, halogen

atom, or C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

W¹ is optionally-substituted C₁₋₄ alkylene group;

5 W²-Q² is -NR^{3a}C(O)-Q², -NR^{3a}C(O)O-Q², -NR^{3a}C(O)OCH₂-Q², -NR^{3a}C(O)NR^{3b}-Q², -NR^{3a}C(O)NR^{3b}CH₂-Q², -NR^{3a}C(O)CH₂O-Q², -NR^{3a}C(O)CH₂-Q², -NR^{3a}C(O)CH₂CH₂-Q², -C(O)NR^{3a}-Q², -C(O)NR^{3a}CH₂-Q², or -C(O)NR^{3a}CH₂CH₂-Q² wherein R^{3a} and R^{3b} are independently hydrogen atom or C₁₋₆ alkyl group;

10 ring Q² is 5- to 10-membered heteroaryl group;

W³ is optionally-substituted C₁₋₄ alkylene group, optionally-substituted C₃₋₄ alkenylene group, or optionally-substituted C₃₋₄ alkynylene group;

n is 1, 2, 3, 4, or 5;

15 R⁴ is, independently when two or more exist, hydrogen atom, halogen atom, optionally-substituted C₁₋₆ alkyl group, optionally-substituted C₁₋₆ alkoxy group, optionally-substituted C₃₋₁₀ cycloalkyl group, optionally-substituted C₂₋₆ alkenyl group, optionally-substituted C₂₋₆ alkynyl group,
20 cyano group, or optionally-substituted amino group;

when R⁴ and W³ are attached to the adjacent carbon atoms on ring Q², they may be combined with the carbon atoms to form 5- to 8-membered cycloalkane ring; and

R⁵ is

25 (1) hydroxy group,

(2) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, C₁₋₆ alkoxy, and C₆₋₁₀ aryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(3) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups, or

(4) C₁₋₆ alkyl-carbonylamino group wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 halogen atoms.

3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof wherein ring Q¹ is

(1) C₆₋₁₀ aryl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of

(a) halogen atom,

(b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected

from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(d) cyano,

(e) C₆₋₁₀ aryl which may be optionally substituted with the
5 same or different 1 to 4 groups independently selected from
the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆
alkoxy,

(f) 5- or 6-membered heteroaryl which may be optionally
substituted with the same or different 1 to 4 groups
10 independently selected from the group consisting of halogen
atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(g) C₆₋₁₀ aryloxy which may be optionally substituted with
the same or different 1 to 4 groups independently selected
from the group consisting of halogen atom, C₁₋₆ alkyl, and
15 C₁₋₆ alkoxy,

(h) hydroxy,

(i) amino which may be optionally substituted with the
same or different 1 to 2 C₁₋₆ alkyl groups,

(j) aminocarbonyl wherein the amino moiety thereof may be
20 optionally substituted with the same or different 1 to 2
C₁₋₆ alkyl groups,

(k) C₁₋₆ alkoxy-carbonyl wherein the alkoxy moiety thereof
may be optionally substituted with the same or different 1
to 3 groups independently selected from the group
25 consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(l) C₁₋₆ alkyl-carbonyl wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

5 (m) C₁₋₆ alkylsulfonyl wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

10 (n) C₁₋₆ alkyl-carbonylamino wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

15 (o) C₁₋₆ alkylsulfonylamino wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

20 (p) C₁₋₆ alkoxy-carbonylamino wherein the alkoxy moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(q) C₁₋₆ alkyl-carbonyloxy wherein the alkyl moiety thereof may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

25 (r) aminosulfonyl wherein the amino moiety thereof may be

optionally substituted with the same or different 1 to 2
C₁₋₆ alkyl groups, and

(s) C₃₋₁₀ cycloalkyl which may be optionally substituted
with the same or different 1 to 4 groups independently
5 selected from the group consisting of halogen atom, hydroxy,
and C₁₋₆ alkoxy,

(2) C₃₋₁₀ cycloalkyl group which may be optionally
substituted with the same or different 1 to 5 groups
independently selected from the group consisting of (a) to
10 (s) defined in the above item (1), or

(3) 5- to 10-membered heteroaryl group which may be
optionally substituted with the same or different 1 to 5
groups independently selected from the group consisting of
(a) to (s) defined in the above item (1);

15 W¹ is C₁₋₄ alkylene group which may be optionally
substituted with the same or different 1 to 4 groups
independently selected from the group consisting of halogen
atom, hydroxy, and C₁₋₆ alkoxy;

W³ is

20 (1) C₁₋₄ alkylene group which may be optionally substituted
with the same or different 1 to 4 groups independently
selected from the group consisting of halogen atom, hydroxy,
and C₁₋₆ alkoxy,

(2) C₃₋₄ alkenylene group which may be optionally
25 substituted with the same or different 1 to 2 halogen atoms,

or

(3) C₃₋₄ alkynylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms;

5 R⁴ is, independently when two or more exist,

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently
10 selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently
15 selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(5) C₃₋₁₀ cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups
independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

20 (6) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(7) C₂₋₆ alkynyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(8) cyano group, or

25 (9) amino group which may be optionally substituted with

the same or different 1 to 2 C₁₋₆ alkyl groups; and

when R⁴ and W³ are attached to the adjacent carbon atoms on ring Q², they may be combined with the carbon atoms to form 5- to 8-membered cycloalkane ring.

5

4. The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof wherein ring Q¹ is

(1) phenyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of

10 (a) halogen atom,
(b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

15 (c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

20 (d) cyano,
(e) phenyl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

25

(f) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy, and

5 (g) phenoxy which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, C₁₋₆ alkyl, and C₁₋₆ alkoxy,

(2) C₃₋₇ cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of (a) to (g) defined in the above (1), or

10

(3) pyridyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of (a) to (g) defined in the above (1).

15

5. The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof wherein ring Q¹ is phenyl group which may be optionally substituted with the same or different 1 to 5 groups independently selected from the group consisting of

20

(a) halogen atom,

(b) C₁₋₆ alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

25

(c) C₁₋₆ alkoxy which may be optionally substituted with the same or different 1 to 3 halogen atoms.

6. The compound according to any one of claims 1 to 5 or
5 a pharmaceutically acceptable salt thereof wherein W¹ is methylene group which may be optionally substituted with 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with 1 to 4 halogen atoms.

10 7. The compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof wherein W²-Q² is -NR^{3a}C(O)-Q², -NR^{3a}C(O)CH₂O-Q², or -C(O)NR^{3a}-Q² wherein R^{3a} is hydrogen atom or C₁₋₆ alkyl group.


15 8. The compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof wherein W²-Q² is -NHC(O)-Q² or -C(O)NH-Q².

20 9. The compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof wherein ring Q² is pyridyl group, pyrimidyl group, pyridazyl group, pyrazyl group, oxazolyl group, thiazolyl group, isoxazolyl group, isothiazolyl group, quinolinyl group, isoquinolinyl group, quinazolinyl group, or quinoxalinyl group.

10. The compound according to any one of claims 1 to 9 or
a pharmaceutically acceptable salt thereof wherein ring Q²
is pyridyl group, pyridazyl group, pyrazyl group, oxazolyl
group, thiazolyl group, isoxazolyl group, or quinolinyl
5 group.

11. The compound according to any one of claims 1 to 10 or
a pharmaceutically acceptable salt thereof wherein W³ is
methylene group which may be optionally substituted with
10 the same or different 1 to 2 halogen atoms, or ethylene
group which may be optionally substituted with the same or
different 1 to 4 groups independently selected from the
group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy;
and R⁵ is hydroxy group or C₁₋₆ alkoxy group which may be
15 optionally substituted with the same or different 1 to 3
groups independently selected from the group consisting of
halogen atom, hydroxy, and C₁₋₆ alkoxy.

12. The compound according to claim 1 represented by
20 formula (1a'):



or a pharmaceutically acceptable salt thereof, wherein ring Q^{1a} is phenyl group, pyridyl group, or cyclohexyl group;

m is 1, 2, 3, 4, or 5;

R^{11} is, independently when two or more exist,

- 5 (1) hydrogen atom,
(2) halogen atom,
(3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or
(4) C_{1-6} alkoxy group which may be optionally substituted
10 with the same or different 1 to 3 halogen atoms;

R^1 and R^2 are independently hydrogen atom, halogen atom, or C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

- 15 W^{1a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with the same or different 1 to 4 halogen atoms;

$W^{2a}-Q^{2a}$ is $-NR^{3a}C(O)-Q^{2a}$, $-NR^{3a}C(O)CH_2O-Q^{2a}$, $-C(O)NR^{3a}-Q^{2a}$,
20 or $-NR^{3a}C(O)-CH=CH-Q^{2a}$ wherein R^{3a} is hydrogen atom or C_{1-6} alkyl group;

ring Q^{2a} is 5- or 6-membered heteroaryl group;

W^{3a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms,
25 or ethylene group which may be optionally substituted with

the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy;


R¹² and R¹³ are independently

- 5 (1) hydrogen atom,
- (2) halogen atom,
- (3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy,
- 10 and C₁₋₆ alkoxy,
- (4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,
- 15 (5) C₃₋₁₀ cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,
- (6) C₂₋₆ alkenyl group which may be optionally substituted
- 20 with the same or different 1 to 2 halogen atoms,
- (7) C₂₋₆ alkynyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,
- (8) cyano group, or
- (9) amino group which may be optionally substituted with
- 25 the same or different 1 to 2 C₁₋₆ alkyl groups;

when R^{13} and W^{3a} are attached to the adjacent carbon atoms on ring Q^{2a} , they may be combined with the carbon atoms to form 5- or 6-membered cycloalkane ring; and

R^{14} is hydroxy group or C_{1-6} alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy.

13. The compound according to claim 1 represented by formula (1a):



or a pharmaceutically acceptable salt thereof, wherein ring Q^{1a} is phenyl group, pyridyl group, or cyclohexyl group;

m is 1, 2, 3, 4, or 5;

R^{11} is, independently when two or more exist,

- (1) hydrogen atom,
- (2) halogen atom,
- (3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or
- (4) C_{1-6} alkoxy group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

R^1 and R^2 are independently hydrogen atom, halogen atom, or C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

5 W^{1a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with the same or different 1 to 4 halogen atoms;

10 $W^{2a}-Q^{2a}$ is $-NR^{3a}C(O)-Q^{2a}$, $-NR^{3a}C(O)CH_2O-Q^{2a}$, or $-C(O)NR^{3a}-Q^{2a}$ wherein R^{3a} is hydrogen atom or C_{1-6} alkyl group;

 ring Q^{2a} is 5- or 6-membered heteroaryl group;

W^{3a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or ethylene group which may be optionally substituted with
15 the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy;

R^{12} and R^{13} are independently

- (1) hydrogen atom,
20 (2) halogen atom,
 (3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy,
25 (4) C_{1-6} alkoxy group which may be optionally substituted

with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(5) C₃₋₁₀ cycloalkyl group which may be optionally substituted with the same or different 1 to 4 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(6) C₂₋₆ alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(7) C₂₋₆ alkynyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms,

(8) cyano group, or

(9) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups;

when R¹³ and W^{3a} are attached to the adjacent carbon atoms on ring Q^{2a}, they may be combined with the carbon atoms to form 5- or 6-membered cycloalkane ring; and

R¹⁴ is hydroxy group or C₁₋₆alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy.

14. The compound according to claim 12 or 13 or a pharmaceutically acceptable salt thereof wherein ring Q^{1a} is phenyl group.

15. The compound according to any one of claims 12 to 14
or a pharmaceutically acceptable salt thereof wherein W^{2a} -
 Q^{2a} is $-NHC(O)-Q^{2a}$.

5

16. The compound according to any one of claims 12 to 15
or a pharmaceutically acceptable salt thereof wherein ring
 Q^{2a} is pyridyl group, pyrimidyl group, pyridazyl group,
pyrazyl group, oxazolyl group, thiazolyl group, isoxazolyl
10 group, or isothiazolyl group.

17. The compound according to any one of claims 12 to 15
or a pharmaceutically acceptable salt thereof wherein ring
 Q^{2a} is pyridyl group, pyridazyl group, pyrazyl group,
15 oxazolyl group, thiazolyl group, or isoxazolyl group.

18. The compound according to any one of claims 12 to 15
or a pharmaceutically acceptable salt thereof wherein ring
 Q^{2a} is pyridyl group.

20

19. The compound according to any one of claims 12 to 18
or a pharmaceutically acceptable salt thereof wherein R^{12}
and R^{13} are independently

(1) hydrogen atom,

25

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

5 (4) C₁₋₆ alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy,

(5) C₂₋₆ alkenyl group which may be optionally substituted
10 with the same or different 1 to 2 halogen atoms, or

(6) amino group which may be optionally substituted with the same or different 1 to 2 C₁₋₆ alkyl groups.

20. The compound according to any one of claims 12 to 19
15 or a pharmaceutically acceptable salt thereof wherein R¹² and R¹³ are independently

(1) hydrogen atom,

(2) halogen atom,

(3) C₁₋₆ alkyl group which may be optionally substituted
20 with the same or different 1 to 3 groups independently selected from the group consisting of halogen atom, hydroxy, and C₁₋₆ alkoxy, or

(4) amino.

25 21. The compound according to any one of claims 12 to 20

or a pharmaceutically acceptable salt thereof wherein R^{13} is halogen atom, C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or amino; and R^{12} is hydrogen atom.

5


22. The compound according to any one of claims 12 to 21 or a pharmaceutically acceptable salt thereof wherein W^{3a} is methylene group which may be optionally substituted with the same or different 1 to 2 halogen atoms; and R^{14} is hydroxy group.

10

23. The compound according to any one of claims 1 to 22 or a pharmaceutically acceptable salt thereof wherein R^1 and R^2 are hydrogen atom.

15

24. The compound according to claim 1 represented by formula (1b):



or a pharmaceutically acceptable salt thereof, wherein X^1 is N or CR^{26} ;

20

X^2 is N or CR^{28} ;

provided that at least one of X^1 and X^2 is N;

R^{21} , R^{22} , R^{23} , R^{24} , and R^{25} are independently

(1) hydrogen atom,

(2) halogen atom,

5 (3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or

(4) C_{1-6} alkoxy group which may be optionally substituted with the same or different 1 to 3 halogen atoms;

W^{2b} is $-NHC(O)-$ or $-C(O)NH-$; and

10 R^{26} , R^{27} , R^{28} , and R^{29} are independently

(1) hydrogen atom,

(2) halogen atom,

(3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 groups independently
15 selected from the group consisting of halogen atom, hydroxy, and C_{1-6} alkoxy,

(4) C_{1-6} alkoxy group which may be optionally substituted with the same or different 1 to 3 groups independently
selected from the group consisting of halogen atom, hydroxy,
20 and C_{1-6} alkoxy,

(5) C_{2-6} alkenyl group which may be optionally substituted with the same or different 1 to 2 halogen atoms, or

(6) amino group which may be optionally substituted with the same or different 1 to 2 C_{1-6} alkyl groups.

25. The compound according to claim 24 or a pharmaceutically acceptable salt thereof wherein R^{22} is halogen atom or C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms.

5

26. The compound according to claim 24 or a pharmaceutically acceptable salt thereof wherein R^{22} is halogen atom or trifluoromethyl group.

10 27. The compound according to any one of claims 24 to 26 or a pharmaceutically acceptable salt thereof wherein R^{21} , R^{23} , R^{24} , and R^{25} are independently

(1) hydrogen atom,

(2) halogen atom, or

15 (3) C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms.

28. The compound according to any one of claims 24 to 27 or a pharmaceutically acceptable salt thereof wherein W^{2b}
20 is $-NHC(O)-$.

29. The compound according to any one of claims 24 to 28 or a pharmaceutically acceptable salt thereof wherein X^1 is N.

25

30. The compound according to any one of claims 24 to 29 or a pharmaceutically acceptable salt thereof wherein X^1 is N; and X^2 is CH.

5 31. The compound according to any one of claims 24 to 30 or a pharmaceutically acceptable salt thereof wherein R^{27} is halogen atom, C_{1-6} alkyl group which may be optionally substituted with the same or different 1 to 3 halogen atoms, or amino group; and R^{29} is hydrogen atom.

10

32. The compound according to any one of claims 24 to 31 or a pharmaceutically acceptable salt thereof wherein R^{27} is methyl group substituted with 1 to 3 fluorine atoms; and R^{29} is hydrogen atom.

15

33. The compound according to claim 1 selected from the following compounds or a pharmaceutically acceptable salt thereof:

6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 10),
20 6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide (Example 12),
5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide
25 (Example 17),

5-(difluoromethyl)-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 18),

6-(hydroxymethyl)-5-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl]nicotinamide

5 (Example 19),

6-(hydroxymethyl)-5-methyl-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 39),

6-(hydroxymethyl)-5-methyl-N-[1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl]nicotinamide

10 (Example 42),

5-amino-6-(hydroxymethyl)-N-[1-[3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl]nicotinamide

(Example 45),

5-amino-6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]nicotinamide (Example 46),

N-[1-(3,4-difluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 54),

N-[1-(3-chlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 55),

20 5-(difluoromethyl)-N-[1-[4-fluoro-3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl]-6-(hydroxymethyl)nicotinamide (Example 57),

5-(difluoromethyl)-N-[1-[3-fluoro-5-(trifluoromethyl)benzyl]-1H-imidazol-4-yl]-6-

25 (hydroxymethyl)nicotinamide (Example 60),

N-[1-(3-chloro-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 61),

N-[1-(3-bromo-4-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 62),

5 5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[3-methoxy-5-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide (Example 65),

5-(difluoromethyl)-6-(hydroxymethyl)-N-{1-[4-methyl-3-(trifluoromethyl)benzyl]-1H-imidazol-4-yl}nicotinamide
10 (Example 70),

N-[1-(3,4-dichlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 71),

N-[1-(3,5-dichlorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 75),

15 N-[1-(3-bromo-5-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 76),

N-[1-(3-chloro-5-fluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 78),

20 N-[1-(3,5-difluorobenzyl)-1H-imidazol-4-yl]-5-(difluoromethyl)-6-(hydroxymethyl)nicotinamide (Example 79),

and

6-(hydroxymethyl)-N-[1-(3,4,5-trifluorobenzyl)-1H-imidazol-4-yl]pyridazine-3-carboxamide (Example 85).

25 34. A medicament comprising the compound according to any

one of claims 1 to 33 or a pharmaceutically acceptable salt thereof as an active ingredient.

35. An anti-tumor agent comprising the compound according to any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof as an active ingredient.

36. The anti-tumor agent according to claim 35 wherein the tumor is acute leukemia, chronic lymphatic leukemia, chronic myelocytic leukemia, polycythemia vera, malignant lymphoma, myeloma, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, stomach cancer, gallbladder or bile duct cancer, liver cancer, pancreatic cancer, colon cancer, rectal cancer, ovarian cancer, chorioepithelioma, endometrial cancer, cervical cancer, urothelial cancer, renal cell cancer, prostate cancer, testicular tumor, Wilms' tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, or soft tissue sarcoma.

37. A medicament comprising the compound according to any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof in combination with another anti-cancer agent selected from the group consisting of an anticancer

alkylating agent, an anticancer antimetabolite, an anticancer antibiotic, a plant-based anti-cancer agent, an anticancer platinum coordination compound, an anticancer camptothecin derivative, an anticancer tyrosine kinase
5 inhibitor, a serine-threonine kinase, a phospholipid kinase, a monoclonal antibody, an interferon, a biological response modifier, a hormone preparation, an immune checkpoint inhibitor, an epigenetics-related molecule inhibitor, a post-translational protein modification inhibitor, and
10 other anti-cancer agent or a pharmaceutically acceptable salt thereof.

38. Use of the compound according to any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof for the
15 manufacture of an agent for treating cancer.

39. A pharmaceutical composition for the treatment of cancer comprising the compound according to any one of claims 1 to 33 or a pharmaceutically acceptable salt
20 thereof.

40. The compound according to any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof for the use in treating cancer.